

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> C12N 15/12, A61K 37/02 C12P 21/08, C07K 13/00, 15/28	<b>A1</b>	<b>(11) International Publication Number:</b> WO 94/08007 <b>(43) International Publication Date:</b> 14 April 1994 (14.04.94)
<b>(21) International Application Number:</b> PCT/US93/09298 <b>(22) International Filing Date:</b> 29 September 1993 (29.09.93)  <b>(30) Priority data:</b> 07/953,742 29 September 1992 (29.09.92) US  <b>(71) Applicant:</b> PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US).  <b>(72) Inventors:</b> FISCHBACH, Gerald, D. ; 75 Cambridge Parkway, #206, Cambridge, MA 02142 (US). FALLS, Douglas, L. ; 19 Strawberry Hill Road, Natick, MA 01760 (US). ROSEN, Kenneth, M. ; 1461 VFW Parkway, West Roxbury, MA 02132 (US). CORFAS, Gabriel ; 119 Browne Street, #1, Brookline, MA 02146 (US).		<b>(74) Agents:</b> VINCENT, Matthew, P. et al.; Lahive & Cockfield, 60 State Street, Boston, MA 02109 (US).  <b>(81) Designated States:</b> AU, CA, JP, KR, NZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> TROPHIC FACTOR HAVING ION CHANNEL-INDUCING ACTIVITY IN NEURONAL CELLS  <b>(57) Abstract</b>  The invention pertains to isolated neurotrophic factors, designated as ARIA, which are able to induce the formation of ion channels in a surface membrane of a cell. The amino acid sequence of the neurotrophic factors include an EGF-like domain, and a second amino acid sequence encoded by at least a portion of an exon of the neurotrophic factor gene expressible in a cell of the nervous system, such as a neuronal cell. The neurotrophic factor is distinct from, and essentially unrelated to, the chicken prion-like protein previously identified.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

## TROPIC FACTOR HAVING ION CHANNEL-INDUCING ACTIVITY IN NEURONAL CELLS

Background of the Invention

5           The formation of functional contacts between developing axons and their targets is an essential step in the establishment of neuronal circuits. At the neuromuscular junction (nmj), as at other chemical synapses, the number and distribution of neuro-transmitter receptors are critical factors in determining the response to presynaptic stimulation. The neuromuscular  
10       junction is the best understood chemical synapse. Most of what is known about chemical synapses in the brain was either first or most completely analyzed at the nerve-muscle synapse. The transmitter at the nmj, acetylcholine (ACh) was identified more than 50 years ago. The ACh Receptor (AChR) was the first receptor/ion channel to be purified. It is composed of four subunits encoded by four different genes.

15           A cardinal event in the formation of the NMJ is the accumulation of acetylcholine receptors (AChRs) in the muscle membrane opposed to the nerve terminal. At the mature junction, receptors are packed in the postsynaptic membrane at a density in excess of 20,000 receptors/sq-micrometer. The localization is striking in that more than 70% of the receptors are concentrated to the motor endplate, a region that comprises less than 0.1 percent of the  
20       muscle-surface membrane.

          Before the arrival of the motor nerve, nicotinic AChRs are distributed relatively uniformly over the surface of muscle fibers. The distribution of receptors can be mapped physiologically by measuring the sensitivity of the muscle membrane with an intracellular recording electrode while applying ACh iontophoretically from an extracellular microelectrode  
25       filled with 1M ACh and placed at different points over the muscle surface. The distribution of receptors can also be visualized using radiolabeled or fluorochrome labeled  $\alpha$ -bungarotoxin (BgTx), a snake venom protein that binds selectively and almost irreversibly to nicotinic AChR (the type of AChR in skeletal muscle), or with monoclonal antibodies directed against extracellular regions of the receptor.

30           These labeling techniques reveal a dramatic change in the distribution of AChRs after innervation of the muscle fiber. There is a large increase in the density of receptors at the site of innervation and a decrease in the density of receptors at extrasynaptic sites. AChRs begin to accumulate at developing junctions within a few hours after nerve-muscle contact and the onset of synaptic transmission. This phenomenon has been studied extensively in cell  
35       cultures containing embryonic motor neurons and myotubes. Individual synaptic partners can be visualized directly and monitored over periods of time that extend from seconds to several days.

          Although a few AChRs and AChR clusters are present on uninnervated embryonic

myotubes and myoblasts, it is clear that ingrowing motor nerves induce new receptor clusters rather than seeking out pre-existing ones (Anderson et al. 1977 *J. Physiol.* 268: 757; Frank and Fischbach 1979 *J. Cell Biol* 83: 142). At least two processes contribute to the accumulation of AChRs at developing synaptic junctions. First, motor neurons may promote  
5 the aggregation of receptors that were present on the myocyte before nerve-muscle contact. These receptors may diffuse within the plane of the membrane and become immobilized at the synaptic site, presumably by binding to sites within the cytoskeleton and/or extracellular matrix. Second, motor neurons may induce the target muscle to increase the synthesis and insertion of new receptors in the immediate vicinity of the synapse. At chick synaptic  
10 junctions, the majority of AChRs at newly formed synapses or neurite associated receptor patches (NARPs) are newly inserted (Role et al., 1985 *J. Neurosci* 5: 2197).

The motor nerve terminal triggers other changes in the properties of the postsynaptic receptor. For instance, AChRs at junctional sites lose their ability to diffuse in the plane of the membrane and gradually become fixed at the site of the synapse. Additionally, AChRs at  
15 junctional sites have a much longer half-life than extrajunctional receptors. AChRs found at newly formed end-plates in embryonic chicks have a half-life of about 24 hours, which is similar to that of extracellular receptors. With increasing time after synapse formation, junctional receptors become more stable, turning over with a half-life of more than 120 hours, whereas extrajunctional receptors are not stabilized.

The motor nerve also induces a change in the functional properties of nicotinic AChRs after skeletal muscle is innervated. AChR channels in embryonic rat muscle have a relatively small conductance (about 30pS) but remain open for long periods (about 5-10mS) and have therefore been termed slow channels. In contrast, junctional receptors at mature  
20 end-plates have a significantly larger conductance (about 50pS) but remain open for a much shorter period (usually only about 1mS) and are called fast channels.

AChRs at mature mammalian neuromuscular junctions are pentameric protein complexes composed of four subunits in the ratio of  $\alpha_2\beta\epsilon\delta$  (Mishina et al. 1986 *Nature* 321: 406; Gu et al. 1988 *Neuron* 1: 117, incorporated by reference herein). Most, if not all, embryonic AChRs contain a different subunit, termed " $\gamma$ ", in place of the  $\epsilon$  subunit. When  
30 mixtures of  $\alpha, \beta, \delta$ , and  $\gamma$  subunit mRNAs are injected into *Xenopus* oocytes, the expressed channels have the properties of embryonic receptors. When transcripts encoding the  $\epsilon$ -subunit are substituted for the  $\gamma$ -subunit, the resulting channels have the properties of adult receptors. It is likely that this change in subunit composition, which occurs during the first 2 weeks after birth and is due to a switch in gene expression, accounts for the switch in  
35 properties of ACh-activated channels from slow channels to fast channels which occurs over approximately the same time course.

The influence of the nerve on the AChR distribution appears to be mediated at least in part by diffusible factors released by the presynaptic nerve terminal. For instance, myotubes located close to a spinal cord explant have been shown to be more sensitive to iontophoretically applied ACh and bind more  $^{125}\text{I}$ -BgTx than do myotubes located some distance away (Cohen and Fischbach, 1977 *Devel. Biol.* 59:24). Acetylcholine itself does not seem to be the molecule responsible for the clustering of AChRs, as evidenced by the lack of AChR clustering in response to local application of ACh, and the observation that receptor clustering can occur when all AChRs are blocked by drugs such as curare.

Progress has been made in identifying a putative trophic factor that can increase the rate of receptor insertion, and that can promote the transition from embryonic to adult-type nicotinic AChRs. An Acetylcholine Receptor-Inducing Activity (ARIA) has been partially purified from adult chicken brains (Jessell et al., 1979 *PNAS* 76: 5397; Buc-Caron et al., 1983 *Div. Biol.* 95: 378; Usdin and Fischbach 1986 *J. Cell Biol* 103: 493). The purification was based on a sensitive assay in which the initial rate of appearance of new surface membrane AChRs are measured with  $^{125}\text{I}$ -BgTx four hours after blocking all exposed (old) receptors with unlabeled BgTx (Devreotes and Fambrough, 1975 *J. Cell Biol* 65: 335). The purified protein was shown to increase the rate of AChR synthesis several fold with a  $K_{\text{app}}$  in the picomolar range. ARIA does not appear to increase total protein synthesis or alter the degradation of surface receptors, but has been shown to affect the levels of certain AChR subunit mRNAs (Harris et al., 1988 *PNAS* 85: 7669).

This activity was shown to co-migrate with a protein that migrates as a broad band centered at an apparent MW of 42kd by SDS-PAGE (Usdin et al. 1986 *J. Cell Biol.* 103:493). A chicken prion-like protein (Ch-PrLP) emerged as a major protein and apparently the only sequenceable protein in preparations of this activity (Falls et al. (1990) *Cold Spring Harbor Symp. Quant. Biol.* 55: 397). Based on N-terminal amino acid sequence analysis, oligonucleotides, were generated having sequences corresponding to portions of the chemically determined sequence of the protein present in the SDS-polyacrylamide band in which the activity was present, and were used to isolate a cDNA from an embryonic chick cDNA library. The isolated cDNA encodes a chicken protein that is homologous to the mammalian prion protein (PrPc). This chicken prion-like protein (ch-PrLP) was shown to be identical to the mouse PrP at 33% of its amino acid positions, and appeared to contain similar structural domains (Harris et al. 1991 *PNAS* 88: 7664, incorporated by reference herein). However, the Ch-PrLP was not active when expressed, and anti-Ch-PrLP antibodies do not precipitate receptor-inducing activity.

Summary of the Invention

The invention pertains to isolated neurotrophic factors, designated as ARIA, which are able to induce the formation of ion channels in a surface membrane of a cell. The amino acid sequence of the neurotrophic factors include an EGF-like domain, and a second amino acid sequence encoded by at least a portion of an exon of the neurotrophic factor gene expressible in a cell of the nervous system, such as a neuronal cell. The neurotrophic factor is distinct from, and essentially unrelated to, the chicken prion-like protein previously identified.

The neurotrophic factors of the present invention have a spectrum of action which can include the induction of functional ion channel formation in a membrane of a cell. Examples of such ion channels include directly ligand-gated ion channels, such as acetylcholine receptors, glutamate receptors, GABA receptors and glycine receptors. For example, the neurotrophic factor can cause an increase in the number of nicotinic AChRs, and can effect an accumulation of the receptors in the surface membrane of a cell. Voltage-gated ion channels, such as the voltage-gated Na<sup>+</sup> channel, can also be affected by ARIA treatment. The neurotrophic factor can also induces functional ion channel formation of indirectly ligand-gated ion channels, such as muscarinic acetylcholine receptors. For example the neurotrophic factor of the present invention can increase the number of functional G-protein coupled receptors.

In one embodiment of the invention, the amino acid sequence of one variant of the neurotrophic factor is shown in Figure 1 (SEQ. ID NO. 1).

The factor can be produced by isolating it in its native form from cells or tissue that produce the factor, such as brain tissue, by chemical synthesis, or by recombinant DNA techniques.

This invention additionally pertains to isolated nucleic acid (DNA or RNA) encoding the neurotrophic factor, to cloning or expression vectors containing the nucleic acid, and to cells transformed with these vectors. Another aspect of the invention is direct to antibodies, including monoclonal and polyclonal antibodies, which are directed against the neurotrophic factor.

The neurotrophic factor of this invention, and related proteins having an EGF-like amino acid sequences, such as heregulins and neu differentiation factor (NDF), can be used as either agonists or antagonists, to influence the formation of functional ion channels, such as acetylcholine receptors, in the surface membrane of a postsynaptic cell.

### Brief Description of the Drawings

Figures 1A-D represent the nucleotide (SEQ. ID NO. 1) and amino acid (SEQ. ID NO. 2) sequence of ARIA cloned from a chicken brain cDNA library. The sequences bounded by the numbered brackets are as follows, (1) Nex1, (2) Ig-like domain, (3) Nex2, (4) EGF-like domain, (5) transmembrane domain. Amino acid sequences located C-terminal to the transmembrane domain correspond to the cytoplasmic portion of ARIA, while those amino acid sequences N-terminal to the transmembrane domain are the extracellular portion. Nex1 roughly comprises amino acid residues 1-27, the Ig-like domain comprises residues 45-108, Nex2 roughly comprises amino acid residues 116-127, the EGF-like domain comprises residues 141-180, the transmembrane domain comprises amino acid residues 207-229.

Figure 2 is a schematic representation of the structural domains and motifs of ARIA corresponding to the amino acid sequence of Figures 1A-D.

Figure 3 is an alignment of the EGF-like amino acid sequences of distinct ARIA variants cloned from chicken (SEQ ID NOS. 1, 27, 28 and 29) and rat (SEQ ID NO. 33), with the EGF-like domains of Heregulin- $\beta$  and - $\alpha$  (SEQ ID NOS. 37 and 39), Neu Differentiation Factor- $\beta$  and - $\alpha$  (SEQ ID NOS. 38 and 40), Heparin-binding EGF-like growth factor (SEQ ID NO. 41), amphiregulin (SEQ ID NO. 42), Schwannoma-derived growth factor (SEQ ID NO. 43), Epithelial Growth Factor (SEQ ID NO. 44), and Tumor Necrosis Factor (SEQ ID NO. 45).

### Detailed Description of the Invention

An Acetylcholine Receptor Inducing Activity (ARIA) was previously shown to co-purify from chicken brain extracts, through a number of chromatographic steps, with a protein that migrates as a broad band centered at MW 42,000 in SDS-polyacrylamide gels (Usdin et al. 1986 *J. Cell Biol.* 103:493). A chicken prion-like protein was cloned and identified by screening a chicken brain cDNA library with oligonucleotides derived from the chemically determined sequence of the only apparently sequenceable protein in the purified preparations of ARIA (Harris et al. 1991 *PNAS* 88:7664).

As described herein, a neurotrophic factor, termed ARIA, has been isolated and cloned on the basis of its ability to promote the synthesis and accumulation of AChRs in cultured muscle cells. In one aspect of the invention, purification of endogenous ARIA from chicken brain extracts was accomplished by a series of reverse-phase, ion exchange, and size exclusion chromatography steps. Most recently, we have discovered that ARIA is retained on a heparin column under conditions that do not support the binding of ch-PrLP. Partial amino

acid sequencing of tryptic fractions prepared from the heparin-purified ARIA has allowed cloning of the protein from a chicken cDNA library. The nucleotide sequence, and the corresponding amino acid sequence, of the neurotrophic factor cloned from the messenger library is shown in Figure 1. The heparin-purified ARIA protein from chicken brain is  
5 believed to be contained within the extracellular domain of this large transmembrane precursor neurotrophic factor. The amino acid sequence of ARIA is entirely distinct from the ch-PrLP previously identified in ARIA-containing chromatographic fractions. As described below, an ARIA homolog has also been cloned from rat, and shares a many domain features with the chicken clone.

10 The cloned cDNA has been expressed in cultured mammalian cells, and can induce an increase in AChR levels in cultured muscle cells. The cloned cDNA that encodes ARIA has been transfected into COS-7 cells, and medium conditioned by the transformed cells stimulates the synthesis of AChRs in skeletal muscle cells. The significant increase in AChR levels indicate that the protein corresponding to the cloned cDNA is in fact ARIA.

15 In cells treated with ARIA, there is not any significant increase in total protein synthesis; rather, ARIA selectively affects the synthesis and/or the number of functional ion channel receptors, or the of molecules that are concentrated at synapses and generally present in low abundance elsewhere on the cellular membrane. For instance, both the cloned and purified endogenous forms of ARIA can induce an increase in the number of nictotinic  
20 acetylcholine receptors in the surface membrane of a cell. The addition of ARIA to either cultured chicken, rat, human or mouse myotubes has been demonstrated to result in an increase in the appearance of new  $\alpha$ -BgTX binding sites in the myotube cultures.

In addition to nicotinic AChRs of the nmj, the spectrum of action of ARIA is likely to include the regulation of a wide range of ion channels and other molecules concentrated at  
25 chemical synapses. For example, ion channels affected by ARIA can include members of the super-family of ligand-gated ion channels (see Betz 1990 *Neuron* 5:383, incorporated herein by reference) including neuronal nicotinic AChRs. For instance, partially purified ARIA increases the response of ciliary ganglion neurons to ACh. Highly purified ARIA phosphorylates a 185kD protein in ciliary ganglion neurons, which as discussed below, is  
30 highly correlated with AChR synthesis. These cells are models for neurons in the brain that exhibit nicotinic AChRs, as they contain similar subunits. Other neurotransmitter receptors of the central nervous system (CNS) such as amino acid receptors for gamma-amino butyric acid (GABA), glycine, and glutamate, which form ligand-gated ion channels having similar organizational and significant amino acid identity with the subunits of the nicotinic AChRs  
35 can be affected by ARIA. GABA and glycine receptors are concentrated beneath inhibitory boutons on central neurons, and glutamate receptors are concentrated at neurite contacts,



presumably excitatory synapses.

Another example of an ion channel likely to be affected by treatment with ARIA is the voltage-gated Na<sup>+</sup> channel, which also shares similar structural motifs with the ligand-gated family of ion channels. This effect is suggested by the observation that ARIA can increase the saxitoxin (STX) binding (two fold) and peak inward Na<sup>+</sup> currents in cultured muscle cells (see Falls et al. 1990 *Cold Spring Harbor Symp. Quant. Biol.* 55:397). Similarly, other voltage-gated ion channels, including Ca<sup>++</sup> channels and K<sup>+</sup> channels, can be affected by ARIA because they are structurally related to Na<sup>+</sup> channels.

Also, ARIA can affect ion channels activated indirectly via G-protein coupled chemoreceptors, such as muscarinic AChRs. This action of ARIA is supported by the observation that ARIA-containing brain extract increases the ACh response of ventricular cardiac muscle cells (see Siegel et al. 1984 *Develop. Biol.* 101:346, incorporated herein by reference), and the response is due to activation of muscarinic AChRs.

Thus, the term "ion channels" as used herein is meant to include voltage-gated, directly ligand-gated, and indirectly ligand-gated ion channels.

There presently exists a battery of reagents which are specific for a wide range of ion channels, and will allow the determination of the levels of functional ion channels in the presence and absence of ARIA. Thus, the effect of the neurotrophic factor of the present invention on a particular ion channel can be easily assessed.

Consistent with this understanding that ARIA can be a multifunctional protein whose biological activities may be context dependent, we have studied the expression of ARIA mRNA in the nervous system by *in situ* hybridization using anti-sense RNA probes to the ARIA gene sequences described herein, and have found a pattern of expression indicative of a role for ARIA inclusive of each class of ion channel set out above.

In the rat brain, to illustrate, ARIA mRNA is present in many cholinergic neurons in the brain stem and cerebral hemispheres. In particular, ARIA mRNA was found in motor nuclei of the III, IV, V, VII, IX and X cranial nerves. In the hemispheres it is abundant in the septal nuclei and the diagonal band of Broca. These observations further support the assertion that ARIA regulates ACh receptors in the cerebral cortex (neocortex and hippocampus), and hence may enhance the formation and recall of memory.

ARIA mRNA is also present in non-cholinergic neurons in the brain. For example, the present ARIA mRNA probes detected ARIA message in cells of the pontine nuclei, other thalamic and midbrain nuclei, and granule cells of the cerebellum. These findings are consistent with a role for ARIA in effecting other ion channels. We have also studied the distribution of ARIA mRNA expression in the chick using a probe to the 5' end of a chicken ARIA cDNA. The results are similar to those found in the rat. We have

found that some cholinergic and some non-cholinergic neurons contain ARIA mRNA, many of them being the homologous structures to the ones labeled in the rat brain.

Furthermore, ARIA expression is not limited to neural tissue. In both rat and chick tissue samples, ARIA mRNA level is very high in the endocardium, a monolayer of endothelial cells covering the heart's chambers. In the embryo, the endocardial cells constitute the earliest formed structures of the heart, around which the myocardium then proliferates, and from which the heart's valves are formed. While the function of the endocardium is still in question, it has been proposed that it constitutes an important modulator of the performance of the subjacent myocardium (Brutsaert, (1989) *Annual Rev. Physiol.* 51:263-273). It is conceivable that ARIA produced by the endocardium plays a role in the proliferation and differentiation of the heart muscles as well as in the modulation of its electrical and mechanical properties. This is further supported by the observation that p185 (discussed below) is phosphorylated in myocytes from E5 chick embryos in response to treatment with ARIA.

Indeed, labeling studies in chick brain samples during various stages of development tend to support the concept of a broader involvement for ARIA in biological function beyond just ion channel induction, which can include mitogenic as well as growth factor-like activities. For example, ARIA mRNA is present in proliferating neuronal populations. This is most clear in the cerebellar granule cells, which express ARIA mRNA while located in the External Granule Cell Layer, where they undergo cell division. They continue to express ARIA mRNA immediately after migrating to the Internal Granule Cell Layer, the position that they will retain in the adult brain.

The present invention makes available isolated ARIA which is substantially free of prion-like protein and recombinant ARIA produced by the expression of the cloned ARIA gene or a fragment thereof. The term "substantially free of prion-like protein" is defined herein as encompassing ARIA preparations comprising less than 20% (by dry weight) prion-like protein, and preferably comprises less than 5% prion-like protein. Functional forms of ARIA can be prepared, for the first time, as purified preparations by using a cloned gene as described herein. By "purified", it is meant, when referring to a peptide or DNA or RNA sequence, that the indicated molecule is present in the substantial absence of other biological macromolecules, such as other proteins (particularly other trophic factors, as well as prion-like proteins). The term "purified" as used herein preferably means at least 80% by dry weight, more preferably in the range of 95-99% by weight, and most preferably at least 99.8% by weight, of biological macromolecules of the same type present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 5000, can be present). The term "pure" as used herein

preferably has the same numerical limits as "purified" immediately above. The term "isolated" as used herein refers to a peptide, DNA, or RNA molecule separated from other peptides, DNAs, or RNAs, respectively, that are present in the natural source of the macromolecule. "Isolated" and "purified" do not encompass either natural materials in their native state or natural materials that have been separated into components (e.g., in an acrylamide gel) but not obtained either as pure (e.g. lacking prion-like proteins) substances or solutions.

ARIA can be used to supplement cell culture media for growth of postsynaptic target cells (e.g. muscle or nerve cells), and provide a means for examining changes in ion channel states, which may ordinarily require complex procedures for co-culturing of several nerve cell-types. For instance, the neurotrophic factor, or an active fragment thereof, can cause an increase in synthesis of nicotinic AChRs, and can effect an accumulation of the receptors in the surface membrane of a cell. The neurotrophic factor can regulate a phenotypic change in nicotinic AChRs from slow to fast channels, as well as increase the level of mRNA encoding the  $\alpha$ - and  $\epsilon$ -subunits of the receptor. Thus, augmentation of the culture medium with the neurotrophic factor of this invention can allow further definition of the events triggered by innervation.

The neurotrophic factor of the present invention can be used to produce anti-ARIA antibodies using known techniques. Both monoclonal and polyclonal antibodies (Ab) directed against ARIA, and antibody fragments such as Fab and F(ab)<sub>2</sub>, can be used to block the action of ARIA and allow the study of the formation of neurite-associated receptor patches (NARPS) at developing nerve-muscle and nerve-nerve synapses in the absence, or controlled presence, of ARIA. For instance, such studies can be carried out in nerve and muscle cell co-cultures.

The effect of anti-ARIA Abs on NARP formation can also be assayed *in vivo*, such as in intact embryos. For instance, purified monoclonal Abs can be injected directly into the limb buds of E5 chick embryos. It has been demonstrated that the motor axons enter the limb bud on E4.5, and the first clusters of AChRs are detectable with  $\alpha$ -BgTx late in E5. Thus, the use of anti-ARIA Abs during this developmental stage can allow assessment of the effect of ARIA on the formation of neuron-muscle synapses *in vivo*. In a similar approach, hybridomas producing anti-ARIA monoclonal Abs, or biodegradable gels in which anti-ARIA Abs are suspended, can be implanted at a site proximal or within the area at which ARIA action is intended to be blocked. Experiments of this nature can aid in deciphering the role of other factors that may be involved in NARP formation.

Antibodies which specifically bind ARIA epitopes can also be used in immunohistochemical staining of tissue samples in order to evaluate the abundance and

pattern of expression of ARIA and ARIA homologs. Anti-ARIA antibodies can be used diagnostically in immuno-precipitation and immuno-blotting to detect and evaluate ARIA levels in tissue or bodily fluid as part of a clinical testing procedure. For instance, such measurements can be useful in predictive valuations of the onset or progression of neurological disorders, such as those marked by denervation-like or disuse-like symptoms, or where there is reason to believe that there is a deficiency in ion channels. Likewise, the ability to monitor ARIA levels in an individual can allow determination of the efficacy of a given treatment regimen for an individual afflicted with such a disorder. The level of ARIA can be measured in bodily fluid, such as in samples of cerebral spinal fluid, or can be measured in tissue, such as produced by biopsy. Diagnostic assays using anti-ARIA antibodies can include immunoassays to aid in early diagnosis of Alzheimer's disease, as a decrease in nicotinic AChRs in the cerebral cortex occurs in this dementing disorder. Other immunoassays involving anti-ARIA antibodies may include tests for diagnosing early stages of myasthenia gravis, and amyotrophic lateral sclerosis.

Another application of anti-ARIA antibodies is in the immunological screening of cDNA libraries constructed in expression vectors such as  $\lambda$ gt11,  $\lambda$ gt18-23,  $\lambda$ ZAP, and  $\lambda$ ORF8. Messenger libraries of this type, having coding sequences inserted in the correct reading frame and orientation, can produce fusion proteins. For instance,  $\lambda$ gt11 will produce fusion proteins whose amino termini consist of  $\beta$ -galactosidase amino acid sequences and whose carboxy termini consist of a foreign polypeptide. Antigenic epitopes of ARIA can then be detected with antibodies, as for example reacting nitrocellulose filters lifted from infected plates with anti-ARIA antibodies. Phage, scored by this assay, can then be isolated from the infected plate. Thus, the presence of ARIA and ARIA homologs can be detected and cloned from other sources. The fact that ARIA from either chicken or rat will induce AChR insertion in myotubes of other species, including human, suggests a certain homology must exist between the homologs of ARIA from evolutionarily diverse sources. Thus, screening a human fusion protein library with an anti-ARIA antibody raised against ARIA from a non-human species can also allow the cloning of a human ARIA.

The nucleotide sequence determined from the cloning of ARIA from both chicken and rat will further allow for the generation of probes designed for use in identifying ARIA homologs in other animals, especially humans. For instance, as described in Example Seven, such probes can be used, in known methods, to screen both messenger and genomic DNA libraries for the presence of homologous sequences ostensibly arising from an ARIA-like gene encoding an ARIA homolog. As above, each technique can facilitate the cloning of a human homolog of ARIA.

In addition, nucleotide probes can be generated, as described in Example Nine, from

the cloned sequence of ARIA, which allow for histological screening of intact tissue and tissue samples for the presence of ARIA mRNA. Similar to the diagnostic uses of anti-ARIA antibodies, the use of probes directed to ARIA mRNA, or to genomic ARIA sequences, can be used for both predictive and therapeutic evaluation of neurological disorders. Used in conjunction with anti-ARIA antibody immunoassays, the nucleotide probes can help facilitate the determination of the molecular basis for a neurological disorder which may involve some abnormality associated with ARIA. For instance, variation in ARIA synthesis can be differentiated from a change in ARIA metabolism (such as increased catabolism).

Also, similar to the antibody blocking experiments, the use of anti-sense techniques (e.g. microinjection of antisense molecules, or transfection with plasmids whose transcripts are anti-sense with regard to ARIA mRNA) can be used to study synapse formation in a controlled ARIA environment by inhibiting endogenous ARIA production. Such techniques can be utilized in cell culture, but can also be used in the creation of transgenic animals.

The neurotrophic factor described herein can be used to treat (prevent and/or reduce the severity of) a number of neurological disorders in which modulation of ion channel levels or ion channel activity can be of therapeutic value. The term "neurological disorders" includes diseased or abnormal states in an individual which can include degenerative growth and development disorders, as well as degenerative diseases. Such neurological disorders can affect the central nervous system or the peripheral nervous system, or both. Also included are altered memory and decline in cognitive functions, as for example, resulting from normal aging processes. Neurological disorders which may be amenable to treatment with ARIA agonists or antagonists may also include any disease where levels of ARIA metabolism are altered and therefor ion channel levels or activity are abnormal.

Examples of neurological disorders which may be treatable with ARIA include Alzheimer's disease, myasthenia gravis, and dementias associated with diseases such as Huntington's disease and Parkinson's disease.

Also included are neurogenic and myopathic diseases which ultimately affect the somatic division of the peripheral nervous system and are manifest as neuromuscular disorders. Examples include chronic atrophies such as amyotrophic lateral sclerosis, Guillain-Barre syndrome and chronic peripheral neuropathy, as well as other diseases which can be manifest as progressive bulbar palsies or spinal muscular atrophies.

ARIA can also be used in the treatment of autonomic disorders of the peripheral nervous system, which include disorders affecting the innervation of smooth muscle and endocrine tissue (such as glandular tissue). For instance, tachycardia is usually associated with an abnormally low level or activity of muscarinic AChRs in the striated muscle of the heart and may be treatable with an ARIA agonist. Likewise, atrial cardiac arrhythmias are also

influenced by the activity of the muscarinic AChRs of the heart. Hypertension may be treatable with ARIA antagonists, for instance, by controlling the sensitivity of the sympathetic nervous system to stimulation, or in treating individuals in which abnormalities exist at baroreceptor connections or within the tractus oblongata.

5       ARIA may also be useful as a memory enhancer, especially in young and old subjects. Atropine and scopolamine, which block muscarinic AChR, result in memory loss. Cholinomimetics (which may activate nicotinic as well as muscarinic receptors) enhance memory performance in all age groups. Thus, by increasing ion channel levels, ARIA can act to enhance memory and cognitive functions

10       Also, nicotine itself is a cognitive enhancer. ARIA, by increasing the number of nicotinic receptors, may eliminate the "craving" for nicotine.

In the treatment of such diseases, it may be desirable to administer an ARIA agonist in circumstances where an increase in the level of functional ion channels at a chemical synapse are desired. "Agonist" refers to ARIA, a suitable homolog, or an ARIA or ARIA homolog peptide, capable of promoting at least one of the biological responses normally associated with ARIA. For example, partial proteolytic digestion of ARIA results in smaller peptides, some of which are capable of inducing nicotinic AChR synthesis. Thus, fragments of ARIA may serve as ARIA agonists. The heregulins, NDF and portions thereof, as well as other EGF-like proteins or EGF-like domains, may also be suitable agonists.

20       In other instances, it may be desirable to administer ARIA antagonists, such as a mutant form of ARIA or an ARIA homolog which blocks at least one of the normal actions of ARIA. Such strategies may be part of treating neurological disorders made manifest by an increased activation of ion channels, such as epilepsy. Thus, treatment with ARIA antagonists can down-regulate the ion channels. In the presence of an ARIA antagonist, 25       ARIA has reduced ability to mediate biological responses normally associated with ARIA. Similar to the use of ARIA antagonists, anti-ARIA antibodies can be used to decrease levels of functional ion channel.

The present invention, by making available purified and recombinant ARIA, will allow the development of assays which can be used to screen for drugs which are either 30       agonists or antagonists. By mutagenesis, and other structural surveys of the neurotrophic factor, rationale drug design can be employed to manipulate ARIA or portions thereof, as either agonists or antagonists, as well as facilitate design of small molecule agonists and antagonists.

A nucleotide sequence derived from the cloning of ARIA, encoding all or a selected 35       portion of the protein, can be used to produce a recombinant form of ARIA via microbial or eukaryotic cellular processes. Ligating the polynucleotide sequence into a gene construct,

such as an expression vector, and transforming or transfecting into hosts, either eukaryotic (yeast, avian, insect or mammalian) or prokaryotic (bacterial cells), are standard procedures used in producing other well-known proteins, e.g. insulin, interferons, human growth hormone, IL-1, IL-2, and the like. Similar procedures, or obvious modifications thereof, can be employed to prepare recombinant ARIA, or portions thereof, by microbial means or tissue-culture technology in accord with the subject invention.

The recombinant ARIA protein can be produced by ligating the cloned gene, or a portion thereof, into a vector suitable for expression in either prokaryotic cells, eukaryotic cells, or both. Expression vehicles for production of recombinant ARIA include plasmids and other vectors. For instance, suitable vectors for the expression of ARIA include plasmids of the types: pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids and pUC-derived plasmids for expression in prokaryotic cells, such as *E. coli*.

A number of vectors exist for the expression of recombinant proteins in yeast. For instance, YEP24, YIP5, YEP51, YEP52, pYES2, and YRP17 are cloning and expression vehicles useful in the introduction of genetic constructs into *S. cerevisiae* (see for example Broach *et al.* (1983) in *Experimental Manipulation of Gene Expression*, ed M. Inouye Academic Press, p. 83, incorporated by reference herein). These vectors can replicate in *E. coli* due the presence of the pBR322 ori, and in *S. cerevisiae* due to the replication determinant of the yeast 2 micron plasmid. In addition, drug resistance markers such as ampicillin can be used.

The preferred mammalian expression vectors contain both prokaryotic sequences to facilitate the propagation of the vector in bacteria, and one or more eukaryotic transcription units that are expressed in eukaryotic cells. The pcDNA1/amp, pcDNA1/neo, pRc/CMV, pSV2gpt, pSV2neo, pSV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, pko-neo and pHyg derived vectors are examples of mammalian expression vectors suitable for transfection of eukaryotic cells. Some of these vectors are modified with sequences from bacterial plasmids, such as pBR322, to facilitate replication and drug resistance selection in both prokaryotic and eukaryotic cells. Alternatively, derivatives of viruses such as the bovine papilloma virus (BPV-1), or Epstein-Barr virus (pHEBo, pREP-derived and p205) can be used for transient expression of proteins in eukaryotic cells. The various methods employed in the preparation of the plasmids and transformation of host organisms are well known in the art. For other suitable expression systems for both prokaryotic and eukaryotic, as well as general recombinant procedures, see *Molecular Cloning A Laboratory Manual*, 2nd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press:1989) Chapters 16 and 17, incorporated by reference herein.

In some instances, it may be desirable to express the recombinant ARIA by the use of a baculovirus expression system. Examples of such baculovirus expression systems include pVL-derived vectors (such as pVL1392, pVL1393 and pVL941), pAcUW-derived vectors (such as pAcUW1), and pBlueBac-derived vectors (such as the  $\beta$ -gal containing pBlueBac  
5 III).

Depending in the expression system chosen, the ability to obtain a recombinant protein which is either glycosylated or not can be controlled.

When expression of a portion of ARIA is desired, it may be necessary to add a start codon (ATG) to the oligonucleotide fragment containing the desired sequence to be  
10 expressed. It is well known in the art that a methionine at the N-terminal position can be enzymatically cleaved by the use of the enzyme methionine aminopeptidase (MAP). MAP has been cloned from *E. coli* (Ben-Bassat et al. (1987) *J. Bacteriol.* 169:751-757) and *Salmonella typhimurium* and its *in vitro* activity has been demonstrated on recombinant proteins (Miller et al. (1987) *PNAS* 84:2718-1722). Therefore, removal of an N-terminal  
15 methionine, if desired, can be achieved either *in vivo* by expressing ARIA-derived polypeptides in a host which produces MAP (e.g., *E. coli* or CM89 or *S. Cerevisiae*), or *in vitro* by use of purified MPA (e.g., procedure of Miller et al.).

Alternatively, the coding sequences for the polypeptide can be incorporated as a part of a fusion gene including a nucleotide sequence encoding a different polypeptide. This type  
20 of expression system can be useful under conditions where it is desirable to produce an immunogenic fragment of ARIA. For example, the VP6 capsid protein of rotavirus can be used as an immunologic carrier protein for portions of the ARIA polypeptide, either in the monomeric form or in the form of a viral particle. The nucleic acid sequences corresponding to the portion of ARIA to which antibodies are to be raised can be incorporated into a fusion  
25 gene construct which includes coding sequences for a late vaccinia virus structural protein to produce a set of recombinant viruses expressing fusion proteins comprising a portion of ARIA as part of the virion. It has been demonstrated with the use of immunogenic fusion proteins utilizing the Hepatitis B surface antigen fusion proteins that recombinant Hepatitis B virions can be utilized in this role as well. Similarly, chimeric constructs coding for fusion  
30 proteins containing a portion of ARIA and the poliovirus capsid protein can be created to enhance immunogenecity of the set of polypeptide antigens (see for example EP Publication No. 0259149; and Evans et al. (1989) *Nature* 339:385; Huang et al. (1988) *J. Virol.* 62:3855; and Schlienger et al. (1992) *J. Virol.* 66:2, incorporated by reference herein).

The Multiple Antigen Peptide (MAP) system for peptide-based immunization can be  
35 utilized, wherein a desired portion of ARIA is obtained directly from organo-chemical synthesis of the peptide onto an oligomeric branching lysine core (see for example Posnett *et*



*al.* (1988) *JBC* 263:1719 and Nardelli et al. (1992) *J. Immunol.* 148:914, incorporated by reference herein). Antigenic determinants of ARIA can also be expressed and presented by bacterial cells.

In addition to utilizing fusion proteins to enhance immunogenicity, it is widely appreciated that fusion proteins can also facilitate the expression of proteins, such as ARIA, by the use of secretory-directing signal peptides (e.g., see Achstetter et al. 1992 *Gene* 110:25).

In another common use of fusion proteins, a fusion gene can be created having additional sequences coding for a polypeptide portion of the fusion protein which will facilitate its purification. For example, a fusion gene coding for a purification leader sequence, such as a poly-(His)/enterokinase cleavage site sequence, at the N-terminus of the desired portion of ARIA can allow purification of the expressed ARIA fusion protein by affinity chromatography using a  $\text{Ni}^{2+}$  metal resin. The purification leader sequence can then be subsequently removed by treatment with enterokinase (e.g., see Hochuli et al. 1987 *J. Chromatography* 411:177; and Janknecht et al. *PNAS* 88:8972, incorporated by reference herein).

Techniques for making fusion genes are well known. Essentially, the joining of various DNA fragments coding for different polypeptide sequences is performed in accordance with conventional techniques, employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. Alternatively, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers.

Moreover, variations of the ARIA peptides and DNA molecules are also contemplated as being equivalent to those peptides and DNA molecules that are set forth in more detail, as will be appreciated by those skilled in the art. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar replacement of an amino acid with a structurally related amino acid (i.e. conservative mutations) will not have a major effect on the biological activity of the resulting molecule. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids can be divided into four families: (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine; (3) nonpolar = alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar = glycine, asparagine, glutamine, cystine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. In

similar fashion, the amino acid repertoire can be grouped as (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine histidine, (3) aliphatic = glycine, alanine, valine, leucine, isoleucine, serine, threonine, with serine and threonine optionally be grouped separately as aliphatic-hydroxyl; (4) aromatic = phenylalanine, tyrosine, tryptophan; (5) amide = asparagine, glutamine; and (6) sulfur -containing = cysteine and methionine. (see, for example, Biochemistry, 2nd ed, Ed. by L. Stryer, WH Freeman and Co.:1981). Whether a change in the amino acid sequence of a peptide results in a functional ARIA homolog can be readily determined by assessing the ability of the variant peptide to produce a response in cells in a fashion similar to the wild-type ARIA. Peptides in which more than one replacement has taken place can readily be tested in the same manner.

It has been recently reported that a 45kD protein heregulin- $\alpha$  (HRG- $\alpha$ ) has been cloned from an mRNA-derived MDA-MB231 cell library. In addition, several complementary DNA clones encoding related HRGs were also identified, all the HRGs being similar to some extent to proteins in the epidermal growth factor (EGF) family (Holmes et al. 1992 *Nature* 256:1205, incorporated by reference herein).

It has also been reported that a 44kD glycoprotein secreted by transformed rat fibroblasts, termed Neu differentiation factor (NDF), has been cloned and expressed (Wen et al. 1992 *Cell* 69:559, incorporated by reference herein).

The amino acid sequence of the cloned neurotrophic factor ARIA demonstrates a high degree of sequence homology with both rat NDF and the heregulins, especially heregulin- $\beta$ 1. The form of the neurotrophic factor isolated from chicken brain appears to exist *in vivo* as a glycoprotein, and has an apparent molecular weight in the range of 40kd to 45kd when electrophoretically chromatographed on a 13% SDS-polyacrylamide gel. Similar to rat NDF and human heregulins, ARIA identified in both chicken and rat possess an immunoglobulin-like domain as well as an EGF-like domain. However, ARIA also contains two stretches of amino acid residues in the amino terminal half of the extracellular domain, referred to herein as Nex-1 and Nex-2, which can be divergent in sequence from the corresponding amino acid positions in rat NDF and the human heregulins, as well as other growth factors and mitogens including SDGF and the Glial Growth Factors.

As described in Examples Seven and Eight, using probes directed to nucleotide sequences determined in either the chicken ARIA clone or the rat NDF clone, rat spinal cord mRNA was reverse transcribed and the cDNA amplified by PCR. In one instance, a 230 bp fragment was amplified and cloned into a bacterial fusion expression system. The sequence of the PCR fragment indicated substantial homology with ARIA purified from chicken as well as heregulin- $\beta$ 1. This fragment, which corresponds to the EGF-like amino acid sequence of chicken ARIA, has been expressed, isolated, and applied to muscle cell cultures.

This rat ARIA fragment causes phosphorylation of p185, as observed with ARIA isolated from chicken brain. While the EGF-like domain of rat ARIA is closely homologous in sequence to heregulin- $\beta$ , consistent with the above assertion rat ARIA appears to be divergent in sequence from rat NDF and the heregulins at nucleotide positions roughly corresponding to  
5 Nex-1 and Nex-2 of the chicken ARIA (though one rat ARIA clone is identical at Nex-2 to HRG- $\beta$ ). Evidence supporting this observation includes the demonstration of the lack of ability of PCR primers, based on 5' sequences of NDF or heregulin, to amplify sequences (especially 5' to the nucleotides encoding the Ig-like domain), in conjunction with 3' probes that have been shown to bind appropriately to rat ARIA in other reactions, indicating that the  
10 5' sequences of rat NDF and heregulin messages are not present in spinal cord.

Thus, the neurotrophic factors of this invention contain an EGF-like amino acid sequence and an amino acid sequence encoded by at least a portion of an exon of the neurotrophic factor gene expressed in a neuronal cell, preferably a nerve cell. The factors can also contain an immunoglobulin-like domain, a transmembrane domain and a cytoplasmic  
15 domain. The biological activity of the factor with respect to inducing the synthesis of functional ion channels is believed to require the EGF-like domain of the protein. The overall "domain" structure of ARIA cloned from chicken is shown in Figure 2, and the domain structure of the various rat clones is consistent with this depiction.

The cysteinyl-bounded core amino acid sequence of the EGF family of mitogens has  
20 the consensus sequence  $CY_1CY_2CY_3CY_4CY_5C$ , where C is a cysteine,  $Y_1$  represents 7 amino acids which can be the same or different,  $Y_2$  represents 4 to 5 amino acids which can be the same or different,  $Y_3$  represents 10 to 13 amino acids which can be the same or different,  $Y_4$  represents any amino acid, and  $Y_5$  represents 8 amino acids which can be the same or different, and is generally 36-40 residues in length. Based on this general  
25 arrangement of cysteine residues, a closely related motif, termed EGF-like motif, has been identified in a number of proteins. As used herein, an EGF-like amino acid sequence is a sequence which exhibits the EGF-like motif as represented by the general formula  $CX_1CX_2CX_3CX_4CX_5C$ , where C is a cysteine,  $X_1$  represents 4 to 14 amino acids which can be the same or different,  $X_2$  represents 3 to 8 amino acids which can be the same or different,  
30  $X_3$  represents 4 to 14 amino acids which can be the same or different,  $X_4$  is any amino acid, and  $X_5$  represents 8 to 14 amino acids which can be the same or different. Examples of EGF-like amino acid sequences are given in SEQ ID NOS. 2, 4, and 26-43)

Amino acid sequences expressed in neuronal cells include the Nex-1 and Nex-2 amino acid sequences, which as stated above, can be highly divergent in sequence relative to NDF  
35 and the heregulins. It is likely that Nex-1 and Nex-2 arise by way of differential splicing. As is illustrated by the diveristy of ARIA homologs cloned from both chicken and rat, within a

population of cells of the nervous system, other exons may be substituted in other ARIA homologs.

This invention further contemplates a method of generating sets of combinatorial mutants of ARIA, and is especially useful for identifying potential variant sequences (e.g. homologs) that are functional in binding to a receptor for ARIA. The purpose of screening such combinatorial libraries is to generate, for example, novel ARIA homologs which can act as either agonists or antagonist, or alternatively, possess novel activities all together. To illustrate, novel EGF-like domains (e.g. those not naturally occurring in ARIA) can be engineered by the present method to provide more efficient binding to an ARIA receptor yet still retain at least a portion of an activity associated with ARIA. Thus, combinatorially-derived homologs can be generated to have an increased potency relative to a naturally occurring ARIA. Likewise, ARIA homologs can be generated by the present combinatorial approach to act as antagonists, in that they are able to bind an ARIA receptor yet not induce any biological response, thereby blocking the action of ARIA or an ARIA agonist. Moreover, manipulation of certain domains of ARIA by the present method can provide domains more suitable for use in fusion proteins, such as one that incorporates portions of other proteins which are derived from the extracellular matrix and/or which bind extracellular matrix components.

As described herein, ARIA has been cloned from several sources, including chicken and rat, and ARIA from either species has been shown to be active in inducing ion channel formation in human myotubes. Moreover, as described above, cDNA-derived amino acid sequences have become available for other apparent trophic factors that are sufficiently similar to indicate common ancestry with ARIA. These related proteins have a similar domain structure including an EGF-like domain and an Immunoglobulin-like domain. Interestingly, variants of ARIA were cloned from chicken mRNA derived from both spinal cord and cerebellum mRNA libraries that included a stop codon positioned in place of the C5 cyteine of the EGF-like domain (SEQ ID NOS. 27 and 29), giving rise to truncated ARIA porteins. While the role of such truncation variants of ARIA is not known, such mutations may give rise to antagonistic variants of ARIA.

In one aspect of this method, the amino acid sequences for a population of ARIA variants or other related proteins are aligned, preferably to promote the highest homology possible. Such a population of variants can include, for example, naturally occurring ARIA and ARIA homologs from one or more species, as well as amino acid sequences of other proteins, such as those derived from the heregulin family, which are known to, or expected to, possess some ability to induce ARIA-like responses in cells. Amino acids which appear at each position of the aligned sequences are selected to create a degenerate

set of combinatorial sequences.

In a preferred embodiment, the combinatorial ARIA library is produced by way of a degenerate library of genes encoding a library of polypeptides which each include at least a portion of potential ARIA sequences. A mixture of synthetic oligonucleotides can be enzymatically ligated into gene sequences such that the degenerate set of potential ARIA sequences are expressible as individual polypeptides (such as discrete EGF-like domains), or as a set of larger fusion proteins containing the set of ARIA sequences therein.

As illustrated in Figure 3, to analyze the sequences of a population of variants, the amino acid sequences of interest can be aligned relative to sequence homology. The presence or absence of amino acids from an aligned sequence of a particular variant is relative to a chosen consensus length of a reference sequence, which can be real or artificial. In order to maintain the highest homology in alignment of sequences, deletions in the sequence of a variant relative to the reference sequence can be represented by an amino acid space (\*), while insertional mutations in the variant relative to the reference sequence can be disregarded and left out of the sequence of the variant when aligned. For instance, Figure 3 includes the alignment of several EGF-like domains of various cloned forms of ARIA from different species. The sequences are aligned by the conserved cysteine residues present in each variant. Analysis of the alignment of only the EGF-like domains of the ARIA clones shown in Figure 3 can give rise to the generation of a degenerate library of polypeptides comprising potential EGF-like sequences represented by the general formula:

Cys-Xaa(1)-Xaa(2)-Lys-Xaa(3)-Lys-Xaa(4)-Phe-Cys-Val-Asn-  
Gly-Gly-Xaa(5)-Cys-Xaa(6)-Xaa(7)-Val-Lys-Asp-Lys-Xaa(8)-  
Xaa(9)-Pro-Xaa(10)-Arg-Tyr-Leu-Cys-Xaa(11)-Cys-Xaa(12)-  
Asn-Glu-Phe-Thr-Gly-Asp-Arg-Cys

or,

Cys-Xaa(1)-Xaa(2)-Lys-Xaa(3)-Lys-Xaa(4)-Phe-Cys-Val-Asn-  
Gly-Gly-Xaa(5)-Cys-Xaa(6)-Xaa(7)-Val-Lys-Asp-Lys-Xaa(8)-  
Xaa(9)-Pro-Xaa(10)-Arg-Tyr-Leu-Cys-Xaa(11)

wherein Xaa(1) is an Asp, or Ala; Xaa(2) is an Ile, or Glu; Xaa(3) is a Gln, or Glu; Xaa(4) is an Ala, or Thr; Xaa(5) is a Glu, or Gly; Xaa(6) is a Tyr, or Phe; Xaa(7) is a Met, or Thr; Xaa(8) is a Pro, or Ser; Xaa(9) is an Asn, or Ser; Xaa(10) is a Pro, or Ser; Xaa(11) is an Arg, or Lys; Xaa(12) is a Pro, or Ser.

Further expansion of the combinatorial library can be made, for example, by including amino acids which would represent conservative mutations at one or more of the

degenerative positions of the aligned variants. Inclusion of such conservative mutations can give rise to a library of potential ion channel-inducing activities represented by the formula:

5 Cys-Xaa(1)-Xaa(2)-Lys-Xaa(3)-Lys-Xaa(4)-Phe-Cys-Val-Asn-  
Gly-Gly-Xaa(5)-Cys-Xaa(6)-Xaa(7)-Val-Lys-Asp-Lys-Xaa(8)-  
Xaa(9)-Pro-Xaa(10)-Arg-Tyr-Leu-Cys-Xaa(11)-Cys-Xaa(12)-  
Asn-Glu-Phe-Thr-Gly-Asp-Arg-Cys

10 or,

Cys-Xaa(1)-Xaa(2)-Lys-Xaa(3)-Lys-Xaa(4)-Phe-Cys-Val-Asn-  
Gly-Gly-Xaa(5)-Cys-Xaa(6)-Xaa(7)-Val-Lys-Asp-Lys-Xaa(8)-  
Xaa(9)-Pro-Xaa(10)-Arg-Tyr-Leu-Cys-Xaa(11)

15 wherein Xaa(1) is an Asp, Ala, Glu, Val, Leu, Ile, Gly, Ser, or Thr; Xaa(2) is an Ile, Glu, Asp, Gly, Ala, Val, Leu, Ser, or Thr; Xaa(3) is a Gln, Glu, Asn, or Asp; Xaa(4) is an Ala, Thr, Gly, Val, Leu, Ile, or Ser; Xaa(5) is a Glu, Gly, Asp, Ala, Val, Leu, Ile, Ser, or Thr; Xaa(6) is a Tyr, Phe, or Trp; Xaa(7) is a Met, Thr, Ser, Gly, Ala, Val, Leu, or Ile; Xaa(8) is a Pro, Ser, Gly, Ala, Val, Leu, Ile, or Thr; Xaa(9) is an Asn, Ser, Gln, Gly, Ala, Val, Leu, Ile, or Thr; Xaa(10) is a Pro, Ser, Gly, Ala, Val, Leu, Ile, or Thr; Xaa(11) is an Arg, Lys, or His; Xaa(12) is a Pro, Ser, Gly, Ala, Val, Leu, Ile, or Thr.

In another embodiment, the sequences of heregulins and of neu differentiation factors (NDFs) can be included in the variant population, and used to generate a combinatorial ARIA library. In some instances, it may be desirable to include only the  $\beta$ -type EGF-like domains (e.g. derived from HRG- $\beta$ s and NDF- $\beta$ s), in that the C<sub>5</sub>-C<sub>6</sub> sequences of the  $\alpha$ -type EGF-like domains are much more divergent from ARIA. However, inclusion of the heregulins, NDFs, as well as Heparin-binding EGF-like growth factor (HB-EGF), amphiregulin (AREG), and Schwannoma-derived growth factor (SDGF), each shown in Figure 3, produces a combinatorial library of the general formula:

35 Cys-Xaa(1)-Xaa(2)-Xaa(3)-Xaa(4)-Xaa(5)-Xaa(6)-Xaa(7)-Cys-  
Xaa(8)-Xaa(9)-Xaa(10)-Gly-Xaa(11)-Cys-Xaa(12)-Xaa(13)-  
Xaa(14)-Xaa(15)-Xaa(16)-Xaa(17)-Xaa(18)-Xaa(19)-Xaa(20)-  
Xaa(21)-Xaa(22)-Xaa(23)-Xaa(24)-Cys-Xaa(25)-Cys-Xaa  
(26)-Xaa(27)-Xaa(28)-Xaa(29)-Xaa(30)-Gly-Xaa(31)-Arg-Cys

40 or,

Cys-Xaa(1)-Xaa(2)-Xaa(3)-Xaa(4)-Xaa(5)-Xaa(6)-Xaa(7)-Cys-

Xaa(8)-Xaa(9)-Xaa(10)-Gly-Xaa(11)-Cys-Xaa(12)-Xaa(13)-  
 Xaa(14)-Xaa(15)-Xaa(16)-Xaa(17)-Xaa(18)-Xaa(19)-Xaa(20)-  
 Xaa(21)-Xaa(22)-Xaa(23)-Xaa(24)-Cys-Xaa(25)

5 wherein Xaa(1) is an Asp, Ala, Leu, or Asn; Xaa(2) is an Ile, Glu, Arg, or Ala; Xaa(3) is  
 a Lys, or Glu; Xaa(4) is a Gln, Glu, Tyr, or Phe; Xaa(5) is a Lys, or Gln; Xaa(6) is an  
 Ala, Thr, Asp, or Asn; Xaa(7) is a Phe; Xaa(8) is a Val, or Ile; Xaa(9) is an Asn, or His;  
 Xaa(10) is a Gly, or an amino acid gap; Xaa(11) is a Glu, or Gly; Xaa(12) is a Tyr, Phe,  
 Lys, or Arg; Xaa(13) is a Met, Thr, or Tyr; Xaa(14) is a Val, or Ile; Xaa(15) is a Lys, or  
 10 Glu; Xaa(16) is an Asp, Glu, His, or Asn; Xaa(17) is a Leu; Xaa(18) is a Pro, Ser, Arg,  
 or an amino acid gap; Xaa(19) is an Asn, Ser, Ala, or an amino acid gap; Xaa(20) is a  
 Pro, or an amino acid gap; Xaa(21) is a Pro, Ser, or Glu; Xaa(22) is an Arg, Ala, Val, or  
 an amino acid gap; Xaa(23) is a Tyr, Val, or an amino acid gap; Xaa(24) is a Leu, Thr, or  
 an amino acid gap; Xaa(25) is an Arg, Lys, Ile, or His; Xaa(26) is a Pro, Ser, Gln, or His;  
 15 Xaa(27) is an Asn, Pro, or Gln; Xaa(28) is a Glu, Gly, or Asp; Xaa(29) is a Phe, or Tyr;  
 Xaa(30) is a Thr, His, or Phe; and Xaa(31) is an Asp, Ala, or Glu. In this context, an  
 amino acid gap is understood to mean the deletion of that amino acid position from the  
 resulting peptide. For example, where above Xaa(8) is Val, Xaa(9) is Asn, and Xaa(10) is  
 an amino acid gap. That portion of the EGF-like sequences would have the formula -Cys-  
 20 Val-Asn-Gly-, rather than -Cys-Val-Asn-Gly-Gly where Xaa(10) is a glycine residue

In similar fashion, the degeneracy provided by the inclusion of an EGF and TGF- $\alpha$   
 sequence can produce a combinatorial library of EGF-like domains having the general  
 formula:

25 Cys-Xaa(1)-Xaa(2)-Xaa(3)-Xaa(4)-Xaa(5)-Xaa(6)-Xaa(7)-Cys-  
 Xaa(8)-Xaa(9)-Xaa(10)-Gly-Xaa(11)-Cys-Xaa(12)-Xaa(13)-  
 Xaa(14)-Xaa(15)-Xaa(16)-Xaa(17)-Xaa(18)-Xaa(19)-Xaa(20)-  
 Xaa(21)-Xaa(22)-Xaa(23)-Xaa(24)-Cys-Xaa(25)-Cys-Xaa(26)-  
 Xaa(27)-Xaa(28)-Xaa(29)-Xaa(30)-Gly-Xaa(31)-Arg-Cys

30

or,

35 Cys-Xaa(1)-Xaa(2)-Xaa(3)-Xaa(4)-Xaa(5)-Xaa(6)-Xaa(7)-Cys-  
 Xaa(8)-Xaa(9)-Xaa(10)-Gly-Xaa(11)-Cys-Xaa(12)-Xaa(13)-  
 Xaa(14)-Xaa(15)-Xaa(16)-Xaa(17)-Xaa(18)-Xaa(19)-Xaa(20)-  
 Xaa(21)-Xaa(22)-Xaa(23)-Xaa(24)-Cys-Xaa(25)

Wherein Xaa(1) is an Asp, Ala, Leu, Asn, or Pro; Xaa(2) is an Ile, Glu, Arg, Ala, Leu, or  
 Asp; Xaa(3) is a Lys, Glu, or Ser; Xaa(4) is a Gln, Glu, Tyr, Phe, or His; Xaa(5) is a  
 40 Lys, Gln, Asp, or Thr; Xaa(6) is an Ala, Thr, Asp, Asn, Gly, or Gln; Xaa(7) is a Phe, or

Tyr; Xaa(8) is a Val, Ile, Leu, or Phe; Xaa(9) is an Asn, or His; Xaa(10) is a Gly, an amino acid gap, or Asp; Xaa(11) is a Glu, Gly, Val, or Thr; Xaa(12) is a Tyr, Phe, Lys, Arg, or Met; Xaa(13) is a Met, Thr, Tyr, or Phe; Xaa(14) is a Val, Ile, or Leu; Xaa(15) is a Lys, Glu, or Val; Xaa(16) is an Asp, Glu, His, Asn, Ala, or Gln; Xaa(17) is a Leu, or Glu; Xaa(18) is a Pro, Ser, Arg, or an amino acid gap; Xaa(19) is an Asn, Ser, Ala, or an amino acid gap; Xaa(20) is a Pro, or an amino acid gap; Xaa(21) is a Pro, Ser, Glu, or Asp; Xaa(22) is an Arg, Ala, Val, an amino acid gap, or Lys; Xaa(23) is a Tyr, Val, an amino acid gap, or Pro; Xaa(24) is a Leu, Thr, an amino acid gap, or Ala; Xaa(25) is an Arg, Lys, Ile, His, Asn, or Val; Xaa(26) is a Pro, Ser, Gln, His, or Val; Xaa(27) is an Asn, Pro, Gln, Val, or Ser; Xaa(28) is a Glu, Gly, or Asp; Xaa(29) is a Phe, or Tyr; Xaa(30) is a Thr, His, Phe, Ile, or Val; and Xaa(31) is an Asp, Ala, or Glu. However, it is noted that as the ability of EGF and TGF- $\alpha$  to induce ARIA-like responses in a cell has been tested and found to be negligible, such a combinatorial library is likely to have a significant population of ARIA antagonists as well as peptides unable to bind an ARIA receptor. The former being separable from the later by its ability to bind such a receptor in a panning assay, such as described below.

In another embodiment, a degenerate sequence library can be created to be entirely random, within the general restrictions of EGF-like sequences, between C1 and C2 as well as C5 and C6, as these sequence are the most varied between the chicken and rat clones of ARIA as well as the heregulins and NDF. Such a library can be represented by the general formula

Cys-Z-Cys-Val-Asn-Gly-Gly-Xaa(1)-Cys-Xaa(2)-Xaa(3)-Val-  
Lys-Asp-Lys-Xaa(4)-Xaa(5)-Pro-Xaa(6)-Arg-Tyr-Leu-Cys-  
Xaa(7)-Cys-Y-Cys

wherein Xaa(1) is a Glu, or Gly; Xaa(2) is a Tyr, or Phe; Xaa(3) is a Met, or Thr; Xaa(4) is a Pro, or Ser; Xaa(5) is an Asn, or Ser; Xaa(6) is a Pro, or Ser; Xaa(7) is an Arg, or Lys; Xaa(8) is a Pro, or Ser; Z represents 4 to 14 amino acids which can be the same or different; and X<sub>5</sub> represents 8 to 14 amino acids which can be the same or different.

In yet another embodiment, all possible EGF-like sequences can be substituted into ARIA in place of those naturally occurring, and the recombinant molecules tested for activity. In such an embodiment, the EGF-like domain of ARIA is given by the general formula, as set out above, CX<sub>1</sub>CX<sub>2</sub>CX<sub>3</sub>CX<sub>4</sub>CX<sub>5</sub>C, where C is a cysteine, X<sub>1</sub> represents 4 to 14 amino acids which can be the same or different, X<sub>2</sub> represents 3 to 8 amino acids which can be the same or different, X<sub>3</sub> represents 4 to 14 amino acids which can be the same or different, X<sub>4</sub> is any amino acid, and X<sub>5</sub> represents 8 to 14 amino acids which can be the same



or different.

In similar fashion, larger portions of the ARIA homologs can be aligned and used to create combinatorial libraries of potential ARIA homologs. In an illustrative embodiment, combinatorial libraries can be generated to include sequences from the Ig-like domain through the EGF-like domain.

There are many ways by which the library of potential ARIA homologs can be generated from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be carried out in an automatic DNA synthesizer, and the synthetic genes then be ligated into an appropriate gene for expression. The purpose of a degenerate set of genes is to provide, in one mixture, all of the sequences encoding the desired set of potential ARIA sequences. The synthesis of degenerate oligonucleotides is well known in the art (see for example Narang, SA (1983) *Tetrahedron* 39:3; Itakura et al. (1981) *Recombinant DNA, Proc 3rd Cleveland Sympos. Macromolecules*, ed. AG Walton, Amsterdam: Elsevier pp273-289; Itakura et al. (1984) *Annu. Rev. Biochem.* 53:323; Itakura et al. (1984) *Science* 198:1056; Ike et al. (1983) *Nucleic Acid Res.* 11:477), and such techniques have been employed in the directed evolution of other proteins (see, for example, Scott et al. (1990) *Science* 249:386-390; Roberts et al. (1992) *PNAS* 89:2429-2433; Devlin et al. (1990) *Science* 249: 404-406; Cwirla et al. (1990) *PNAS* 87: 6378-6382; as well as U.S. Patents Nos. 5,223,409, 5,198,346, and 5,096,815.

A wide range of techniques are known in the art for screening gene products of combinatorial libraries made by point mutations, and for screening cDNA libraries for gene products having a certain property. Such techniques will be generally applicable to rapid screening of the gene libraries generated by the combinatorial mutagenesis of ARIA and related proteins. The most widely used techniques for screening large gene libraries typically comprises cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates relatively easy isolation of the vector encoding the gene whose product was detected. Each of the illustrative assays described below are amenable to high through-put analysis as necessary to screen large numbers of degenerate ARIA sequences created by combinatorial mutagenesis techniques.

In one embodiment, the combinatorial library is designed to be secreted (e.g. the polypeptides of the library all include a signal sequence but no transmembrane or cytoplasmic domains), and is used to transfect a eukaryotic cell that can be co-cultured with muscle cells. Functional ARIA secreted by the cells expressing the combinatorial library will diffuse to neighboring muscle cells and induce formation of AChR. Using antibodies

directed to AChR epitopes, the pattern of detection of AChR induction will resemble a gradient function, and will allow the isolation (generally after several repetitive rounds of selection) of cells producing active ARIA homologs. Likewise, ARIA antagonists can be selected in similar fashion by the ability of the cell producing a functional antagonist to protect neighboring cells from the effect of ARIA added to the culture media.

To illustrate, target cells (e.g. rat L6 muscle cells) are cultured in 24-well microtitre plates. CHO cells are transfected with the combinatorial ARIA gene library (for instance, cloned into the plasmid pcDNA1/amp as described below) and cultured in a cell culture insert (e.g. Collaborative Biomedical Products, Catalog #40446) that are able to fit into the wells of the microtitre plate. The cell culture inserts are placed in the wells such that recombinant ARIA homologs secreted by the cells in the insert can diffuse through the porous bottom of the insert and contact the target cells in the microtitre plate wells. After a period of time sufficient for functional forms of ARIA to produce a measurable response in the target cells, the inserts are removed and the effect of ARIA on the target cells determined. For example, where the target cell is a muscle cell and the activity desired from the ARIA homolog is the induction of AChR, then fluorescently-labeled BgTx can be used to score for AChR induction in the target cells as indicative of a functional ARIA in that well. Cells from the inserts corresponding to wells which score positive for activity can be split and re-cultured on several inserts, the process being repeated until the active clones are identified.

In yet another screening assay, the candidate ARIA gene products are displayed on the surface of a cell or viral particle, and the ability of particular cells or viral particles to bind an ARIA-binding protein (such as an ARIA receptor) via this gene product is detected in a "panning assay". For example, expression vectors encoding a candidate ARIA sequence that includes a can be used to transfect cells which ordinarily do not bind significantly to a particular ARIA-binding protein (such as an ARIA receptor). For instance, the gene library can be cloned into the gene for a surface membrane protein of a bacterial cell, and the resulting fusion protein detected on the surface of the bacteria (Ladner et al., WO 88/06630; Fuchs et al. (1991) *Bio/Technology* 9:1370-1371; and Goward et al. (1992) *TIBS* 18:136-140). In another embodiment, the transmembrane domain of ARIA can be included in the candidate ARIA gene such that the combinatorial library is membrane bound. Ligand-affinity or panning methods for assessing expression of membrane-bound proteins are also well established (Aruffo et al. (1987) *PNAS* 84: 8573; Seed et al. (1987) *PNAS* 84:3365; and Kiefer et al. (1990) *PNAS* 87:6985). Such panning assays can be carried out using any insolubilized substrate which would act to sequester cells displaying an ARIA homolog, such as, to illustrate, an extracellular portion of

p185<sup>HERB4</sup>. In a similar fashion, fluorescently labeled molecules which bind ARIA can be used to score for potentially functional ARIA homologs. Cells can be visually inspected and separated under a fluorescence microscope, or, where the morphology of the cell permits, separated by a fluorescence-activated cell sorter.

5 In yet another embodiment, the gene library is expressed as a fusion protein on the surface of a viral particle. For instance, in the filamentous phage system, foreign peptide sequences can be expressed on the surface of infectious phage, thereby conferring two significant benefits. First, since these phage can be applied to affinity matrices at very high concentrations, large number of phage can be screened at one time. Second, since  
10 each infectious phage encodes the combinatorial gene product on its surface, if a particular phage is recovered from an affinity matrix in low yield, the phage can be amplified by another round of infection. The group of almost identical *E.coli* filamentous phages M13, fd, and f1 are most often used in phage display libraries, as either of the phage gIII or gVIII coat proteins can be used to generate fusion proteins without disrupting the ultimate  
15 packaging of the viral particle (Ladner et al. PCT publication WO 90/02909; Garrard et al., PCT publication WO 92/09690; Marks et al. (1992) J. Biol. Chem. 267:16007-16010; Griffiths et al. (1993) EMBO J 12:725-734; Clackson et al. (1991) Nature 352:624-628; and Barbas et al. (1992) PNAS 89:4457-4461).

To illustrate, the recombinant phage antibody system (RPAS, Pharmacia Catalog  
20 number 27-9400-01) can be easily modified for use in expressing and screening the present ARIA combinatorial libraries. For instance, the pCANTAB 5 phagemid of the RPAS kit contains the gene which encodes the phage gIII coat protein. The ARIA combinatorial gene library is cloned into the phagemid adjacent to the gIII signal sequence such that it will be expressed as a gIII fusion protein. After ligation, the phagemid is used to  
25 transform competent *E. coli* TG1 cells. Transformed cells are subsequently infected with M13KO7 helper phage to rescue the phagemid and its candidate ARIA gene insert. The resulting recombinant phage contain phagemid DNA encoding a specific candidate ARIA, and display one or more copies of the corresponding fusion coat protein. The phage-displayed candidate ARIAs which are capable of binding an ARIA receptor are selected or  
30 enriched by panning. For instance, the phage library can be applied to cultured skeletal muscle cells (e.g. rat L6 cells, ATCC CRL 1458) at 4°C (to prevent endocytosis), and unbound phage washed away from the cells. The bound phage is then isolated, and if the recombinant phage express at least one copy of the wild type gIII coat protein, they will retain their ability to infect *E. coli*. Thus, successive rounds of reinfection of *E. coli*, and  
35 panning will greatly enrich for ARIA homologs which can then be screened for further biological activities in order to differentiate agonists and antagonists.

We have also discovered that the mechanism of action of ARIA appears to be strongly correlated to the tyrosine phosphorylation of a 185kD (p185) protein present in cells sensitive to ARIA treatment. Western blots of chick, rat, postnatal mouse and human muscle lysates, derived from cells treated with ARIA and developed with an anti-phosphotyrosine antibody, have demonstrated that ARIA induces phosphorylation of p185. Significantly, no ARIA-induced phosphorylation of p185 was observed in cultures of chick fibroblasts that did not contain muscle cells. The treatment of ciliary ganglion neurons with ARIA similarly results in the phosphorylation of p185.

EGF, PDGF and insulin all promote tyrosine phosphorylation of chick muscle protein, but the phosphorylated protein could be easily distinguished from p185. FGF, CSF1 and NGF had no effect at all. None of these factors induced phosphorylation of the same band as ARIA. Moreover, none of the factors increased the synthesis of AChRs in the surface membrane of the cells. Agrin, a protein which has previously been shown to promote the aggregation, but not the synthesis of, AChRs likewise failed to affect the phosphorylation of p185.

ARIA-induced phosphorylation was rapid and transient, a clearly antibody-stained band being visible within 1 minute of treatment of the cells with ARIA. At each stage of chromatographic purification, the phosphorylation of p185 was highly correlated with ARIA fractions scoring positive for ARIA by the receptor-insertion bioassay. In addition to the correlation between fractions which scored positive by receptor bioassays and p185 phosphorylation, both activities exhibited nearly identical dose response curves. Suramin, a drug known to interfere in the binding of many growth factors to their receptors, blocked both the creation of new  $\alpha$ -BTX binding sites as well as p185 phosphorylation with the same dose dependence. Importantly, suramin has no effect on tetrodotoxin (TTX) induced AChR synthesis over the same dose range.

ARIA appears to bind to an extracellular domain of p185, as evidenced by the apparent cross-linking of the two proteins to form  $\approx 400$ kD (p185 dimer plus ARIA) and  $\approx 220$ kD species (p185 plus ARIA).

It is most likely that p185 is a tyrosine kinase, and that binding of ARIA to p185, and the ultimate phosphorylation of p185, is one of the first steps in an ARIA-induced cascade that ultimately regulates ion channel levels, such as by mechanisms similar to the observed regulation of nicotinic AChR subunit expression.

In order to determine if the p185 signal could be accounted for as phosphorylation of the neu proto-oncogene protein (Yarden et al. 1988 *Annu. Rev. Biochem.* 57:443), the ability of all of the ARIA-induced phosphotyrosine band to be precipitated by anti-neu antibodies was tested, as was the ability of anti-Ptyr antibodies to precipitate neu in ARIA treated cells.

Two monoclonal antibodies (Oncogene Science Inc., Catalog Nos. OP15 (Ab3) and OP16L(Ab4)) capable of immunoprecipitating the rat neu protein were used for these experiments: Ab3, an IgG directed against the intracellular domain of neu; and Ab4, an IgG directed against the extracellular domain.

5 L6 cells were treated with chick brain purified ARIA for 1 hour. Treated and control cells were lysed in Tris buffer solution (pH8) containing 1% NP-40, 150 mM NaCl, 1 mM ortho-vanadate and protease inhibitors. Insoluble components were separated by centrifugation and the supernatant was incubated with either 1) anti-Ptyr conjugated to agarose beads, 2) Ab3 and protein-G agarose beads, or 3) Ab4 and protein-A agarose beads.

10 Experimental results suggest that immunoprecipitation of p185 with the anti-Ptyr antibody is quantitative, while immunoprecipitation of the neu protein by either anti-neu antibody is not. Therefore, and in order to obtain quantitative removal of the neu protein from the supernatant, three consecutive incubations (3 hours each) with fresh batches of antibodies were performed. Thereafter, each batch of beads and the supernatant were tested  
15 for the presence of p185 and the neu protein by western blot.

Anti-Ptyr did not precipitate any detectable amount of neu from control cells, while some neu signal was detected in the precipitates of treated cells. However, most of the neu signal remained in the supernatant, while all the phosphorylated p185 signal was removed by the beads.

20 Using the anti-neu antibodies we were able to remove quantitatively the neu protein from the supernatant. Interestingly in both cases we did not remove the p185 signal completely. In the case of Ab4 some p185 signal was precipitated by the first round of beads, a much smaller amount with the second and none with the third. The amount of precipitated p185 signal nevertheless was much less than the signal left in the final supernatant. Ab3 very  
25 effectively precipitated neu, without bringing down any p185 signal and, in treated cells, substantially all the tyrosine phosphorylated signal remained in the supernatant.

#### *Example One*

#### *AChR Bioassay*

30 Mononucleated cells were dissociated from pectoral muscles of 10-12 day-old chick embryos (E10) as previously described (Buc-Caron et al., 1983 *Dev. Biol.* 95:378). To reduce the number of fibroblasts, the cells were suspended in complete medium and plated in uncoated 100-mm tissue culture dishes (Falcon Labware, Oxnard, CA) for 30 min at 37°C.  
35 Unattached cells were collected and plated in gelatin-coated, 96-well Micro Test culture plates (Falcon Labware) at a density of 50,000/well in 100 µl of Eagle's minimal essential

medium supplemented with horse serum (10% vol/vol), glutamine (1mM), penicillin (50 U/ml), streptomycin (50 µg/ml), and ovotransferrin (40 µg/ml). The cells were fed with 100 µl of medium on days 3 and 5. On day 7 they were fed with 60 µl of medium or 50 µl of medium plus 10 µl of a test fraction, and the number of AChRs was measured 24 h later (see below). Aliquots of column fractions to be assayed were dried in a Speed-Vac centrifuge (Savant Instruments, Inc., Hicksville, NY) and redissolved in complete medium. Samples that contained nonvolatile material were first desalted on Sep-Pak C<sub>18</sub> cartridges (Waters Associates Millipore Corp., Milford, MA). Samples containing <1 µg of protein were supplemented with 10 µg BSA.

To measure the number of surface AChRs the cells were incubated in complete medium containing 5 nM [<sup>125</sup>I]α-BTX for 1 h at 37°C. The cells were washed twice by immersing the plates in 1 liter Ca<sup>++</sup>-free Hank's balanced salt solution (BSS) containing 2% BSA and then solubilized in 150 µl of 1 N NaOH containing sodium deoxycholate (0.5 mg/ml). The amount of [<sup>125</sup>I]α-BTX bound was determined with a gamma counter. Nonspecific binding, taken as the amount of [<sup>125</sup>I]α-BTX bound in the presence of 10<sup>-7</sup> M unlabeled α-BTX, was subtracted in each case.

The rate of incorporation of AChRs into the surface membrane was determined as described by Devreotes and Fambrough (1975) *J. Cell Biol* 65:335, incorporated by reference herein. All receptors exposed on the muscle surface were blocked with unlabeled α-BTX (10<sup>-7</sup> M for 1 h at 37°C). The cells were washed thoroughly, returned to the incubator in 100 µl of fresh medium, and the number of new toxin binding sites was assayed with [<sup>125</sup>I]α-BTX at various intervals thereafter.

α-BTX was iodinated by the chloramine-T-catalyzed reaction (Hunter and Greenwood, 1962 *Nature* 19:495), and monoiodinated derivatives were purified by size exclusion (Sephadex G-10; Pharmacia Fine Chemicals, Inc., Piscataway, NJ) and cation exchange (CM-Sephadex; Pharmacia Fine Chemicals) chromatography. The specific activity of monoiodinated toxin, estimated by competition with known concentrations of unlabeled α-BTX, ranged between 800 and 1200 cpm/fmol in different preparations.

#### *Example Two*

##### *Purification of ARIA*

Purification of ARIA was carried out by reverse-phase, ion exchange, and size exclusion chromatography in the following steps. (1) 3000 frozen adult chicken brains were crushed in dry ice and delipidated by grinding in acetone at -20°C. The slurry was collected on Whatman No. 54 paper (Whatman Chemical Separation Inc., Clifton, NJ), washed with

diethylether (-20°C), and stored at -90°C. Subsequent steps in the extraction were performed at 4°C. (2) The residual brain "mud" was acid extracted with a cocktail of 2% trifluoroacetic acid (TFA), 5% formic acid, 1N hydrochloric acid, 0.1M sodium chloride, 0.01% thiodiglycol, 1µg/mL each of pepstatin, leupeptin, and phenylmethylsulphonyl fluoride, and 10mM EDTA. After centrifugation at 6000rpm for 60 minutes in a GSA rotor (Sorvall Instruments), the supernatant was filtered through Whatman No. 54 paper. (3) The filtered extract was then batch absorbed on a C18 resin that had been preequilibrated with 0.1% TFA. The resin was washed with 0.1% TFA, and material bound to the resin was eluted with isopropyl alcohol. (4) The extract was brought to pH 7.0 with 0.1N NaOH, and centrifuged to remove any precipitate. The neutralized extract was chromatographed on a CM sepharose column equilibrated in 25mM 4-morpholineethanesulfonic acid (MES) (pH6) and eluted with a gradient of sodium chloride (NaCl). (5) Eluate fractions containing ARIA were brought to pH 3.0 with TFA and chromatographed on a Vydac C4 reverse-phase column equilibrated with 0.1% TFA and eluted with a gradient of isopropyl alcohol. (6) ARIA containing fractions were pooled and chromatographed on a heparin-TSK column equilibrated with phosphate-buffer saline (PBS) and eluted with a gradient of NaCl. Each fraction was analyzed for ARIA by receptor insertion assays (see Example one) as well as for the presence of Ch-PrLP by western blot analysis using anti-PrLP antibodies. Fractions scoring positive for ARIA but not Ch-PrLP were pooled. (7) The pooled fractions were chromatographed on a Superdex 75 16/120 gel filtration column (FPLC) equilibrated and run with PBS. (8) The pooled ARIA containing fractions of the Superdex column were chromatographed on a C4 reverse-phased column equilibrated in 0.13 % heptafluorobutyric acid and eluted with a gradient isopropyl alcohol. (9) The ARIA containing C4 fractions were then pooled and chromatographed on a microbore Vydac C18 reverse-phase column equilibrated in 0.1 percent TFA and eluted with a step gradient of acetonitrile in TFA.

### *Example Three*

#### *PCR primers from Tryptic Fragments*

Bioactive eluate fractions of the C18 reverse-phase chromatograph of Example two were assayed for ARIA by the receptor bioassay as well as analyzed by SDS-PAGE visualized by silver staining in order to exclude contaminants. Appropriate fractions were pooled and partially digested with trypsin, the resulting peptides separated by reverse-phase chromatography. The chromatographed fragments were then analyzed by Edman degradation, and two of the chromatographic fractions yielded single sequences. The chemically determined amino acid sequence for each of those tryptic fragments is as follows:

Peptide 1: Asn-Arg-Pro-Glu-Asn-Val-Lys (SEQ. ID NO. 5)

Peptide 2: Ala-Thr-Leu-Ala-Asp-Ala-Gly-Glu-Tyr-Ala-Cys-Arg (SEQ. ID NO. 6)

5

From these amino acid sequences, homology to rat NDF (Yarden et al.) and the human heregulins (Holmes et al.) was noted. The sequence homology with these proteins suggested that Peptide 1 was the more N-terminal peptide fragment of the two. To construct PCR primers, the sense oligonucleotide primer was based on the amino acid sequence of Peptide 1 and the antisense oligonucleotide primer was based on the amino acid sequence of Peptide 2. A set of degenerate oligonucleotide primers for PCR were designed having the following nucleotide sequences.

10

Primer 2S: GICCIGARAAAYGTNAAG (SEQ. ID NO. 7)

15

Primer 2A: CKRCAIGCRTAYTCNCC (SEQ. ID NO. 8)

Wherein primer 2S corresponds to the sense codons of peptide 1, and primer 2A corresponds to the antisense codons of peptide 2.

20

#### *Example Four*

#### *PCR Amplification of ARIA sequences in Spinal Cord RNA*

Chick spinal cord RNA was prepared from the spinal cords of embryonic day 19-20 chicks by the guanidinium thiocyanate/phenol extraction procedure of Chomczynski (Chomczynski U.S. Patent No. 4,843,155; Chomczynski et al. 1987 *Anal Biochem.* 162:156, incorporated by reference herein). Polyadenylated RNA was reverse transcribed using an oligo(dT)<sub>12-18</sub> primer and Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase (see for example *Molecular Cloning, A Laboratory Manual*, Sambrook, Fritsch and Maniatis Eds 1989: Cold Spring Harbor Laboratory Press; Chapter 5, incorporated by reference herein). Basically, 2µg of total RNA was annealed to 1µg of oligo(dT)<sub>12-18</sub> in a 20µL volume of buffer for 30 minutes. The annealing mixture was diluted with reverse transcriptase buffer, dithiothreitol (DTT, 10mM final), and dNTPs (400µM) to a final volume of 50uL. 200U of M-MLV reverse transcriptase (GibCo-BRL, Gaithersburg MD, Catalog No. 8025) were added and the reaction was incubated for 60 minutes at 42°C, then heat inactivated for 15 minutes at 65°C.

35

Using the primers 2S and 2A, PCR was performed on the chick spinal cDNA (see the Mullis U.S. Patent No. 4,683,202, the Norman et al. U.S. Patent No. 4,800,159, and the



Erlich et al. U.S. Patent No. 4,965,188, incorporated by reference herein). Briefly, PCR was performed in a 100 $\mu$ L reaction containing 5 $\mu$ L of the reverse transcription mixture, 400 $\mu$ M dNTPs, 1 $\mu$ g of each primer, 1X Taq DNA polymerase buffer, and 5U of Taq DNA polymerase (Boehringer-Mannheim, Indianapolis, IN, Catalog No. 1146-165). The PCR was carried through 40 cycles of 94°C for 1 minute, 44°C for 1 minute, and 72°C for 1 minute.

The PCR products were run out on an agarose gel and selected bands cut out and purified. From the noted homology with rat NDF, it was predicted that a 94 nucleotide fragment should be amplified by these two primers. From the agarose gel, a 97 nucleotide cDNA from the reverse transcribed chick spinal cord RNA was isolated. The purified products were ligated into the PCR-II vector using the TA Cloning™ Kit (Invitrogen Corp, San Diego CA, Catalog No. K2000) (Clark 1988 *Nucleic Acids Res.* 16:9677; Grahm et al. 1991 *PNAS* 88:10267; and Jarolim et al. 1991 *PNAS* 88:11022, incorporated by reference herein). The cloned inserts were sequenced by dideoxy chain termination (Sanger et al. 1977 *PNAS* 74:5463, incorporated by reference herein). The sequence of the 97 nucleotide long cDNA was determined to be:

97b fragment:

GG CCG GGA AAT GTC AAG ATC CCC AAA AAG CAA AAG AAA  
TAC TCT GAG CTT CAT ATT TAT AGA GCC ACG TTG GCT GAC  
GCT GGG GAA TAC GCC TGC CG (SEQ. ID NO. 9)

*Example Five*

*Screening a  $\lambda$ gt10 Chicken Brain cDNA Library*

The 97-mer fragment was labeled with  $^{32}$ P using the random oligonucleotide priming method (see Feinberg et al. 1983 *Anal. Biochem.* 132:6; and Feinberg et al. 1984 *Anal. Biochem.* 137:266, incorporated by reference herein), [ $\alpha$ - $^{32}$ P]-labeled dCTP and the Primit™ labeling kit (Stratagene, LaJolla, CA), such that labeled probes were generated ranging in size from 10 to 97 nucleotides. These  $^{32}$ p-labeled probes were then used to screen a Ranscht E13 chicken brain cDNA  $\lambda$ gt10 library (See Ranscht et al. 1988, *J. Cell Biol.* 107:1561, incorporated by reference herein).

Briefly, the recombinant phage and plating bacteria were mixed and incubated at 30°C, added to top agarose (2xYT/Mg/Maltose) and the mixture transferred to 2xYT plates. The plates were incubated at 37°C until there were visible but not confluent plaques, and then incubated at 4°C.

Duplicate lifts were made of each cold plate using nitrocellulose filters. The filters

were denatured and then baked at 70°C, *in vacuo*, for 2 hours (see Benton et al. 1977 *Science* 196:180, incorporated by reference herein).

The baked filters were prewashed in 1000µL of 50mM Tris-HCl (PH8), 1M NaCl, 1mM EDTA, and 0.1% SDS at 37°C for about 1 hour. The filters were then pre-hybridized in  
5 40% formamide/6X SSC/0.2% SDS with 100 µg/ml salmon sperm DNA at 37° for about 5.75 hours. The pre-hybridized filters were then hybridized in 40% formamide/6X SSC/0.2% SDS with <sup>32</sup>P-labeled probe (see above) and 100 µg/ml salmon sperm DNA at 37°C overnight, and washed to a final stringency (high) of 0.1X SSC /0.1% SDS at 45°C.

The filters were then exposed to x-ray film at -70°C and autoradiograms developed.  
10 Alignment of the autoradiogram with the original plates from which the nitrocellulose lifts were made allowed scoring for positive hybridization by comparison of silver grain density with the λgt10 plaques. Phage which scored positive for hybridization with the radiolabeled probes were isolated from the agarose plates and rescreened by the above method.

Phage isolated after the second round were subjected to PCR amplification using  
15 primers directed to λgt10 sequences across the EcoRI site in the cI gene. The longest cDNA clone isolated was 2.4kb insert comprising the sequence shown in Figure 1.

#### *Example Six*

##### *Expression of recombinant ARIA*

20

The 2.4 kb cDNA representing the largest chicken ARIA clone was cloned into the unique EcoRI site of the eukaryotic expression vector pcDNAI/Amp (Invitrogen Corp.; San Diego, CA; catalog # V460-20) which contains an SV40 virus origin of replication to allow high level of expression in COS cells. The insert is under the control of the  
25 enhancer/promoter region of the immediate early gene of cytomegalovirus. Constructs were prepared harboring the 2.4 kb cDNA in both the appropriate and the reverse orientation. The different plasmid constructs were prepared after growth in bacteria to produce large enough amounts for transfection experiments.

Plasmid constructs were transfected into monkey COS-7 cells using the DOTAP  
30 Transfection Reagent (Boehringer-Mannheim; Indianapolis, IN; Catalog # 1202-375). Briefly 1.7 µg of a specific plasmid was mixed with 10 µg of DOTAP and allowed to stand for 10 minutes at room temperature. The mixture was then applied to 35 mm dishes of COS-7 cells growing in DMEM with 10% FBS. The transfection mixture was left on the cells for 18 hours. After this incubation the transfection mixture was removed and the medium  
35 replaced with fresh MEM/10% Horse serum/2% Chick embryo extract. The cells were allowed to grow for 48 hours to condition their medium with secreted factors. The

conditioned medium was collected and used either undiluted or at several dilutions in an AChR incorporation rate assay with primary chicken muscle cultures or in phosphorylation assays of p185 on rat L6 cells.

5

*Example Seven**Cloning and Expression of Rat ARIA*

Total RNA was isolated from postnatal day 20 (P20) rat spinal cord by the method of Chomczynski. 2 µg of RNA was annealed to 1 µg of oligo(dT)<sub>12-18</sub> by heating to 65° C for 10 minutes followed by placing the sample on ice for 5 minutes. Reverse transcription buffer, dNTPs (400µM final), DTT (10 mM final), RNase inhibitor, and 400 U of Moloney Murine Leukemia virus Reverse Transcriptase (Gibco-BRL; Gaithersburg, MD) were added in a final reaction volume of 50 µl. The samples were incubated for 1 hour at 42° C followed by 15 minutes at 65° in order to inactivate the enzyme.

15 Rat spinal cord derived cDNA was subjected to polymerase chain reaction using two combinations of primers corresponding to sequences that border the described EGF-like domain of rat NDF (Wen et al. 1992 *Cell* 69:559). The outermost pair of oligonucleotides correspond to the following sequences: GCGCAAACACTTCTTCATCCAC (SEQ. ID NO. 10) (this represents most of the sense coding information for amino acids 162-169, 20 GANTSSST, (SEQ. ID NO. 11), of the rat NDF sequence) and CACCACACACATGATGCCGAC (SEQ. ID NO. 12) (this represents most of the antisense strand corresponding to amino acids 256-262, VGIMCVV, (SEQ. ID NO. 13)). The innermost pair of the oligonucleotides were designed to allow for amplification from the PCR products made using the outer pair of oligonucleotides but they also contained mutations relative to the sequence 25 for rat NDF that would allow for the orientation specific cloning of the PCR product, after restriction enzyme digestion, directly into the bacterial fusion protein expression vector pMAL-p2 (N.E. Biolabs; Beverly, MA; catalog #800). The sequence of the inner oligonucleotides was as follows: CACGACTAGTACTAGCCATCTC (SEQ. ID NO. 14), corresponding to the sense coding information for amino acids 172-179 of rat NDF with mutations that were introduced to create a restriction site for the enzyme ScaI that would 30 cleave exactly between codons and leave the reading frame intact; and CGACAAGCTTCTAGTAGAGTTCC (SEQ. ID NO. 15), corresponding to the antisense strand of the coding information for amino acids 236 - 244 of rat NDF with mutations relative to the original sequence that would create an in-frame stop translation codon as well as a site 35 for the restriction enzyme HindIII that would allow for cloning into the pMAL-p2 vector. Using these combinations of primers, PCR reactions were set up as follows: 2µl of spinal

cord cDNA reverse transcription reaction, 1 µg of each primer, 400 µM dNTPs, Taq DNA Polymerase Reaction buffer and 2.5 U TAQ DNA Polymerase (Boehringer-Mannheim; Indianapolis, IN Catalog # 1146-165). The reactions were cycled as follows: 94°C for 10 minutes, 52°C for 2 minutes, 72°C for 2 minutes, followed by 39 cycles of 94° for 1.5 minutes, 52°C for 1.5 minutes, 72°C for 2 minutes, followed by a final cycle of 94°C for 2 minutes, 52°C for 2 minutes and 72°C for 10 minutes. Products were analyzed by agarose gel electrophoresis.

The expectation based upon the sequence of rat NDF was for a PCR product of 302 bp for the outer primer pair and a PCR product of 215 bp for the inner primer pair. The agarose gel analysis revealed products of 317 and 230 bp respectively for the outer and inner primer pairs. The PCR products were cloned using the vector pCR-II and the TA cloning kit (Invitrogen Corp.; San Diego, CA; catalog #K2000-01). Sequence analysis of these clones indicated that both identified an EGF-like domain corresponding closely to the ARIA identified in chicken, and the human heregulin β-1 sequence. The inner pair of primers contained mutations which allowed for the directed cloning of the cDNA fragment into pMAL-p2. This vector contains the gene for the maltose binding protein (MBP) of *E. coli* connected to a unique group of cloning sites that allow for expression of new sequences as fusion proteins with MBP and their subsequent purification by affinity chromatography on maltose resin. The cloning site also bears a recognition sequence for the factor Xa protease just prior to the site of insertion of foreign cDNAs. The construct also bears an inducible promoter for the fusion allowing for the induction of expression of the fusion protein by adding isopropyl-β-D-thiogalactopyranoside (IPTG) to the culture.

In the vector pMAL-p2, the MBP gene includes information encoding a signal sequence which targets MPB fusion proteins to the periplasmic space. Periplasmic proteins may have appropriate disulfide bond formation and can be purified by less harsh methods than are required for fusion proteins sequestered intracellularly.

A portion of the PCR product described above, which includes the EGF-like domain, was prepared by digestion with *Scal* and *Hind3* and cloned into pMAL-p2 prepared by digestion with *Xmn1* and *Hind3*. This plasmid was transformed into DH5-α bacteria. Sequencing confirmed that the plasmid encoded the expected sequence fused in frame to the maltose binding protein.

For production of the fusion protein, cultures were grown to a density of  $A_{600}=0.5$ , then induced by the addition of IPTG to a final concentration of 0.3mM. The cultures were incubated for an additional 2 hours, then the bacteria were harvested by centrifugation. The pellet was resuspended in a buffer consisting of 30mM trisHCl (pH8.0), 20% sucrose, 1mM EDTA and incubated to this buffer for 5-10 min. The bacteria were again pelleted,

resuspended in ice cold 5mM MgSO<sub>4</sub> and stirred in this solution in an ice water bath for 10 min. The bacteria were again pelleted by centrifugation and the solution was decanted off. This solution is the "Cold Osmotic Shock Fluid" containing the released fusion protein. Presence of the fusion protein was confirmed by SDS polyacrylamide gel analysis.

5        Treatment of L6 cells and chick myotubes with the cold osmotic shock fluid containing rat ARIA fusion protein produces striking phosphorylation of p185 in rat L6 and chick myotubes.

      In the set of experiments described above, PCR was performed using the primer corresponding to the sequence of nucleotides surrounding the EGF-like domain of rat NDF.  
10    As described, in the creation of the EGF-like domain/pMAL fusion vector, the PCR products generated defined the presence of a protein in rat spinal cord harboring a  $\beta$ -1 form of an EGF-like motif.

      In the next set of PCR experiments, primers were chosen in order to amplify the sequence of an NDF related cDNA between the beginning of the EGF-like domain and the  
15    translation stop codon as well as the end of the EGF-like domain and the translational initiator methionine region. The oligonucleotide CATTTTACCTTTCGCTATGAGGAG (SEQ. ID NO. 16) ("3-AI"), which is the antisense strand corresponding to nucleotides 1586-1609 of the rat NDF sequence of Wen et al., was paired in PCR amplification with the  
oligonucleotide GCGCAAACACTTCTTCATCCAC (SEQ. ID NO. 17) ("4-SO"), which  
20    corresponds to nucleotides 821 - 842 of the rat NDF sequence. Using P20 rat spinal cord derived cDNA as a template for PCR, this amplification should have produced a band of 788 bp. The product visualized in this reaction was consistent with this size range but could not be defined within an error of less than approximately +/- 20 bp.

      Further PCR was performed with a pair of primers that would allow for amplification  
25    between the membrane spanning domain of NDF and its N-terminal methionine region. The oligonucleotides corresponded to the following sequences: CACCACACACATGATGCCGAC (SEQ. ID NO. 12) ("4-AO") representing the antisense strand of the sequence of rat NDF between nucleotides 1107 - 1122. The second oligonucleotide used in this PCR contained the sequence CTCATCTTCGGCGAGATGTCTG (SEQ. ID NO. 18) ("3-S1"),  
30    corresponding to nucleotides 322-343 of the rat NDF sequence, the region containing the initiator methionine (underlined in sequence). PCR with these oligonucleotides should have produced an 800 bp product. However, we were unable to amplify any product indicating that the N-terminal sequence of the published NDF sequence was not likely present in the spinal cord form. It is known from the PCR described in the fusion-protein section that the  
35    sequence represented by the oligonucleotide corresponding to nucleotides 1107-1122 (within the transmembrane domain sequence) was present.

Owing to the novel sequences found within the chicken ARIA cDNA, we performed PCR from P20 rat spinal cord cDNA using oligonucleotides that would include the spacer region sequence that is located between the Immunoglobulin (Ig) like domain and the EGF-like domain, the corresponding region of the chicken bearing the described Nex-2, one of the novel sequences. Oligonucleotides were designed based on the rat NDF sequences, and represented the sequence corresponding to: 1) the sense strand of nucleotides 670 - 692, TGCAAAGTGATCAGCAAGTTAGG (SEQ. ID NO. 19) ("7S"), which codes for amino acids 112 - 118 of the rat NDF sequence and 2) the antisense strand of nucleotides 1107 - 1122 of the rat NDF sequence ("4-AO", see above). Compared to the sequence of the published rat NDF cDNA, we expected to obtain a PCR product of 453 however, two prominent PCR products in the range of 350-475 bp were seen (the accuracy of estimation being +/- 10bp) after agarose gel analysis.

Additional PCR amplifications were performed using the oligonucleotide corresponding to the antisense sequence of nucleotides 1107 - 1122 ("4-AO" above) in combination with a sense strand oligonucleotide corresponding to nucleotides 447 - 469 of the published rat NDF sequence, CAGATTGAAAGAAATGAAGAGCC (SEQ. ID NO. 21) ("6S"). After the results of the previous PCR amplifications we would have anticipated products of 691 bp and 589 bp representing both B1 forms (i.e., one corresponding to NDF and the other to ARIA) with either of the different spacer region exons being represented as described above. After analyzing the amplified products on an agarose gel, we identified (+/- 15 bp) a number of bands measuring between 600 and 700bp.

Sequence analysis of the PCR products amplified from the rat spinal cord library revealed that a number of different variants of ARIA exist. Partial amino acid sequences (determined from the nucleotide sequence) for a number of illustrative rat ARIA clones are provided in the sequence listing, namely SEQ ID NOS. 4 and 32-36. As the 5' end of the coding region of each of the rat ARIA clones was not sequencable using primers directed to heregulin/NDF 5' sequences, is believed that this sequence, Nex-1, is unique with respect to the heregulins and NDF.

The Nex-2 exon sequence determined for the rat ARIA clones is shown here to be heterogenous in size. The partial sequencing of the B1-1 clone (SEQ ID NOS. 3 and 4) reveals a Nex-2 sequence that shares considerable homology with the corresponding spacer region between the EGF-like and Ig-like domains of the heregulins. However, other ARIA clones isolated from the rat spinal cord library possess Nex-2 sequences which, while sharing some homology with the heregulins, are truncated so as to be close in size to the Nex-2 sequence identified in chicken ARIA. For instance, Nex-2 can be SASANITIVESNA (SEQ ID NOS. 32, 33, and 35), or TSSS (SEQ ID NO. 36). Interestingly, each of these Nex-2

sequences, when compared to the B1-1 clone and the heregulins, lack at least one of the potential N-linked glycosylation signals present in the spacer sequences. Such a feature, which may arise, for example, by differential splicing, may serve to alter the interaction of ARIA with extracellular matrix components. In a similar fashion, the 5' end of the heregulins contain a potential glycosaminoglycan attachment sequence, as well as a potential nuclear localization signal, which are not present in at least the sequenced chicken ARIA clones, and therefore possibly absent from the rat ARIA.

All of the PCR reactions described herein were performed under the same cycling conditions as were described for the section regarding the preparation of the EGF-like domain for cloning into the pMAL-p2 fusion expression vector. PCR reactions were performed using 5µl of reverse transcription reaction for P20 rat spinal cord cDNA. They all used 1µg of the appropriate primers.

#### *Example Eight*

##### *Further Isolation of chicken ARIA clones*

In similar fashion to the methodology described above in both Examples Five and Seven, partial sequences for a number of other chicken ARIA cDNA clones were obtained using primers designed from the cDNA clone shown in Figures 1A-1D (SEQ ID NO. 1). Using primers to the nucleotides encoding the N-terminal end of the EGF-like domain, RACE PCR was performed on clones, isolated from both spinal and cerebellum mRNA libraries, to obtain sequencing data from the EGF-like domain to the transmembrane domain. SEQ ID NOS. 26-31 present the corresponding amino acid sequences determined for several of these clones. One striking feature, seen in clones from each of the spinal cord and cerebellum libraries, was the presence of a stop codon in the EGF-like domain. For example, the clone C-119 (SEQ ID NO. 27) and S-93 (SEQ ID NO. 29) each have a stop codon in place of the codon for the C5 cyteine of the EGF-like domain (See Figure 3). While the role of such a variant is not yet fully elucidated, it is possible that these variants represent a soluble form of ARIA (e.g. no transmembrane or cytoplasmic domains) that acts antagonistically to ARIA possessing a full EGF-like domain.

#### *Example Nine*

##### *In Situ hybridization with nucelotide probes directed to ARIA sequences*

Tissues were fixed with 4% paraformaldehyhyde in PBS either by immersion (in the case of embryos) or perfusion (in the case of adults). Tissues were then slowly dehydrated

and embedded in paraffin. Tissue sections (7-9  $\mu\text{m}$ ) were collected on gelatinized glass microscope slides. The procedures used for section treatment, hybridizations and washing were as described in Sasson et al (1988) *Development* 104:155-164. Hybridization was carried out at 52°C for approximately 16 hr in 50% deionized formamide, 0.3 M sodium chloride, 20 mM TRIS-HCl (pH 7.4), mM EDTA, 10 mM  $\text{NaPO}_4$  (pH 8), 10% dextran sulfate, 1 x Denhardt's solution, 50  $\mu\text{g/ml}$  total yeast RNA with  $3 \times 10^4$  cpm/  $\mu\text{l}$   $^{35}\text{S}$ -labeled RNA probe under siliconized coverslips. Following hybridizations, coverslips were floated off in 5 x SSC, 10 mM dithiothreitol at 50°C, and washed in 50% formamide, 2 x SSC, 10 mM dithiothreitol at 65°C. Slides were then rinsed in washing buffer, treated with RNase A (20  $\mu\text{g/ml}$ ; SIGMA), and washed at 37°C for 15 min in 2 x SSC and then for 15 min in 0.1 x SSC. Sections were dehydrated rapidly, processed for autoradiography using NTB-2 Kodak emulsion, exposed for 4-28 days at 4°C, and examined using both light and dark field illumination under a microscope.

Chicken ARIA mRNA was identified using a 329 nt fragment corresponding to nt 15 - 344 of the chick ARIA cDNA (SEQ ID NO. 1) as the hybridization probe. The rat probes were similarly derived from the PCR synthesized cDNA (SEQ ID NO. 3) described in Example Seven. The original rat B1-1 was cleaved with Sph I generating two fragments, one of which ("the Ig probe") corresponds to the 5' end of the B1-1 clone up to the end of the sequence that encodes the Ig-like domain. The second fragment ("the EGF probe") extends from the beginning of the spacer domain and ends within the sequence of the transmembrane region as defined by the original PCR primers.

All of the above-cited references and publications are hereby incorporated by reference.

#### Equivalents

Those skilled in the art will recognize, or be able to ascertain, by no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.



## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

5

## (i) APPLICANT:

- (A) NAME: President and Fellows of Harvard College
- (B) STREET: 17 Quincy Street
- (C) CITY: Cambridge
- 10 (D) STATE: MA
- (E) COUNTRY: USA
- (F) POSTAL CODE (ZIP): 02138
- (G) TELEPHONE: (617) 227-7400
- (H) TELEFAX: (617) 227-5941

15

(ii) TITLE OF INVENTION: Neurotrophic Factor

(iii) NUMBER OF SEQUENCES: 45

20

## (iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: ASCII (text)

25

## (v) CURRENT APPLICATION DATA:

APPLICATION NUMBER:

## (vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: US 07/953,742
- 30 (B) FILING DATE: 29-SEP-1992

## (2) INFORMATION FOR SEQ ID NO:1:

35

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2351 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- 40 (D) TOPOLOGY: linear

40

(ii) MOLECULE TYPE: cDNA

45

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 23..1831

50

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAATTCCGGC GTCCTGCGGG GG ATG TGG GCC ACC TCT GAA GGT CCA CTT CAG  
Met Trp Ala Thr Ser Glu Gly Pro Leu Gln

52

55

1

5

10

-40-

	TAC AGC CTG GCA CCA ACA CAG ACG GAC GTC AAC AGC AGT TAC AGC ACA	100
	Tyr Ser Leu Ala Pro Thr Gln Thr Asp Val Asn Ser Ser Tyr Ser Thr	
	15 20 25	
5	GTG CCT CCC AAA TTG AAG GAA ATG GAA AAC CAA GAG GTT GCT GTG GGT	148
	Val Pro Pro Lys Leu Lys Glu Met Glu Asn Gln Glu Val Ala Val Gly	
	30 35 40	
10	CAG AAG CTA GTG CTA AGG TGT GAA ACC ACT TCA GAG TAC CCT GCG CTC	196
	Gln Lys Leu Val Leu Arg Cys Glu Thr Thr Ser Glu Tyr Pro Ala Leu	
	45 50 55	
15	AGA TTC AAA TGG TTA AAG AAC GGG AAG GAA ATA ACG AAA AAA AAC AGA	244
	Arg Phe Lys Trp Leu Lys Asn Gly Lys Glu Ile Thr Lys Lys Asn Arg	
	60 65 70	
20	CCC GAA AAT GTC AAG ATC CCC AAA AAG CAA AAG AAA TAC TCT GAG CTT	292
	Pro Glu Asn Val Lys Ile Pro Lys Lys Gln Lys Lys Tyr Ser Glu Leu	
	75 80 85 90	
25	CAT ATT TAT AGG GCC ACG TTG GCT GAC GCT GGG GAA TAC GCA TGC AGA	340
	His Ile Tyr Arg Ala Thr Leu Ala Asp Ala Gly Glu Tyr Ala Cys Arg	
	95 100 105	
30	GTG AGC AGC AAA CTA GGG AAC GAC AGT ACT AAA GCA AGT GTT ATC ATC	388
	Val Ser Ser Lys Leu Gly Asn Asp Ser Thr Lys Ala Ser Val Ile Ile	
	110 115 120	
35	ACA GAC ACC AAT GCC ACT TCT ACA TCT ACA ACT GGG ACA AGT CAT CTC	436
	Thr Asp Thr Asn Ala Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu	
	125 130 135	
40	ACA AAA TGT GAC ATA AAG CAG AAA GCC TTC TGT GTA AAT GGG GGA GAG	484
	Thr Lys Cys Asp Ile Lys Gln Lys Ala Phe Cys Val Asn Gly Gly Glu	
	140 145 150	
45	TGC TAC ATG GTT AAA GAC CTC CCA AAC CCT CCA CGA TAC CTA TGC AGG	532
	Cys Tyr Met Val Lys Asp Leu Pro Asn Pro Pro Arg Tyr Leu Cys Arg	
	155 160 165 170	
50	TGC CCA AAT GAA TTT ACT GGT GAT CGC TGC CAA AAC TAC GTA ATG GCC	580
	Cys Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val Met Ala	
	175 180 185	
55	AGC TTC TAC AAG CAT CTT GGG ATT GAA TTT ATG GAA GCT GAG GAA CTG	628
	Ser Phe Tyr Lys His Leu Gly Ile Glu Phe Met Glu Ala Glu Glu Leu	
	190 195 200	
60	TAC CAG AAA CGG GTG CTG ACC ATA ACT GGC ATT TGC ATT GCT CTT CTA	676
	Tyr Gln Lys Arg Val Leu Thr Ile Thr Gly Ile Cys Ile Ala Leu Leu	
	205 210 215	
65	GTA GTT GGC ATC ATG TGT GTG GTG GCC TAC TGC AAA ACC AAG AAG CAG	724
	Val Val Gly Ile Met Cys Val Val Ala Tyr Cys Lys Thr Lys Lys Gln	

	220	225	230	
	AGG AAA AAG TTG CAT GAC CGC CTT CGG CAG AGC CTT CGC TCA GAG AGG			772
	Arg Lys Lys Leu His Asp Arg Leu Arg Gln Ser Leu Arg Ser Glu Arg			
5	235	240	245	250
	AAC AAC GTT ATG AAC ATG GCA AAT GGG CCA CAC CAC CCC AAC CCA CCA			820
	Asn Asn Val Met Asn Met Ala Asn Gly Pro His His Pro Asn Pro Pro			
	255	260	265	
10	CCA GAC AAT GTC CAG CTG GTG AAT CAG TAC GTT TCA AAA AAC ATA ATC			868
	Pro Asp Asn Val Gln Leu Val Asn Gln Tyr Val Ser Lys Asn Ile Ile			
	270	275	280	
15	TCC AGT GAA CGT GTC GTT GAG CGA GAA ACC GAG ACC TCG TTT TCC ACA			916
	Ser Ser Glu Arg Val Val Glu Arg Glu Thr Glu Thr Ser Phe Ser Thr			
	285	290	295	
	AGC CAC TAC ACC TCA ACA ACT CAT CAC TCC ATG ACA GTC ACC CAG ACG			964
20	Ser His Tyr Thr Ser Thr Thr His His Ser Met Thr Val Thr Gln Thr			
	300	305	310	
	CCT AGC CAC AGC TGG AGT AAT GGC CAT ACC GAA AGC ATT CTC TCC GAA			1012
	Pro Ser His Ser Trp Ser Asn Gly His Thr Glu Ser Ile Leu Ser Glu			
25	315	320	325	330
	AGC CAC TCC GTG CTC GTC AGC TCC TCA GTG GAG AAT AGC AGG CAC ACC			1060
	Ser His Ser Val Leu Val Ser Ser Ser Val Glu Asn Ser Arg His Thr			
	335	340	345	
30	AGC CCA ACA GGG CCA CGA GGC CGC CTC AAT GGN ATT GGT GGG CCA AGG			1108
	Ser Pro Thr Gly Pro Arg Gly Arg Leu Asn Gly Ile Gly Gly Pro Arg			
	350	355	360	
35	GAA GGC AAC AGC TTC CTC CGG CAT GCA AGA GAG ACC CCT GAC TCC TAC			1156
	Glu Gly Asn Ser Phe Leu Arg His Ala Arg Glu Thr Pro Asp Ser Tyr			
	365	370	375	
	CGA GAC TCT CCT CAC AGT GAA AGG TAT GTC TCA GCT ATG ACC ACA CCA			1204
40	Arg Asp Ser Pro His Ser Glu Arg Tyr Val Ser Ala Met Thr Thr Pro			
	380	385	390	
	GCT CGC ATG TCA CCC GTT GAT TTC CAC ACT CCA ACT TCT CCC AAG TCC			1252
	Ala Arg Met Ser Pro Val Asp Phe His Thr Pro Thr Ser Pro Lys Ser			
45	395	400	405	410
	CCT CCA TCT GAA ATG TCA CCA CCA GTT TCC AGC TTG ACC ATC TCC ATC			1300
50	Pro Pro Ser Glu Met Ser Ser Pro Pro Val Ser Ser Leu Thr Ile Ser Ile			
	415	420	425	
	CCT TCG GTG GCG GTG AGT CCC TTT ATG GAC GAG GAG AGA CCG CTG CTG			1348
55	Pro Ser Val Ala Val Ser Pro Phe Met Asp Glu Glu Arg Pro Leu Leu			

	430	435	440	
	TTG GTG ACC CCA CCA CGG CTG CGT GAG AAG TAC GAC AAC CAC CTT CAG	1396		
	Leu Val Thr Pro Pro Arg Leu Arg Glu Lys Tyr Asp Asn His Leu Gln			
5	445	450	455	
	CAA TTC AAC TCC TTC CAC AAC AAT CCC ACC CAT GAG AGC AAC AGT CTG	1444		
	Gln Phe Asn Ser Phe His Asn Asn Pro Thr His Glu Ser Asn Ser Leu			
	460	465	470	
10	CCA CCC AGT CCT CTG AGG ATA GTG GAG GAT GAA GAG TAT GAG ACC ACG	1492		
	Pro Pro Ser Pro Leu Arg Ile Val Glu Asp Glu Glu Tyr Glu Thr Thr			
	475	480	485	490
15	CAG GAG TAC GAA CCA GCA CAG GAG CCT CCA AAG AAA CTC ACC AAC AGC	1540		
	Gln Glu Tyr Glu Pro Ala Gln Glu Pro Pro Lys Lys Leu Thr Asn Ser			
	495	500	505	
	CGG AGG GTG AAA AGA ACA AAG CCC AAT GGC CAT ATT TCC AGC AGG GTA	1588		
20	Arg Arg Val Lys Arg Thr Lys Pro Asn Gly His Ile Ser Ser Arg Val			
	510	515	520	
	GAA GTG GAC TCC GAC ACA AGC TCT CAG AGC ACT AGC TCT GAG AGC GAA	1636		
	Glu Val Asp Ser Asp Thr Ser Ser Gln Ser Thr Ser Ser Glu Ser Glu			
25	525	530	535	
	ACA GAA GAT GAA AGA ATA GGT GAG GAT ACA CCA TTT CTT AGC ATA CAA	1684		
	Thr Glu Asp Glu Arg Ile Gly Glu Asp Thr Pro Phe Leu Ser Ile Gln			
	540	545	550	
30	AAT CCC ATG NCA ACC AGT CTG GAG CCA GCC TCT GCA TAT CGG CTG GCT	1732		
	Asn Pro Met Xaa Thr Ser Leu Glu Pro Ala Ser Ala Tyr Arg Leu Ala			
	555	560	565	570
35	GAG AAC AGG ACT AAC CCG NCA AAT CGC TTC TCC ACA CCA GAA GAG TTG	1780		
	Glu Asn Arg Thr Asn Pro Xaa Asn Arg Phe Ser Thr Pro Glu Glu Leu			
	575	580	585	
	CAA GCA AGG TTG TCC AGT GTA ATA GCT AAC CAA GAC CCT ATT GCT GTA	1828		
40	Gln Ala Arg Leu Ser Ser Val Ile Ala Asn Gln Asp Pro Ile Ala Val			
	590	595	600	
	TAAGACATAA ACAAACACA TAGATTCACA TGTAACCTT TATTTTATAT AATGAAGTAT	1888		
45	TCCACCTTTA AATTAAACAA TTTATTTTAT TTTAGCAATT CCGCTGATAG AAAACAAGAG	1948		
	TGGA AAAAGA AACTTTTATA AATTAAGTAT ACGTATGTAC AAATGTGTTA TGTGCCATAT	2008		
	GTAGCAATTT TTTACAGTAT TTCCAAAATG GGGAAAGATA TCAATGGTGC CTTTATGTTA	2068		
50	TGTTATGTTG AGAGCAAGTT TTGTACAGCT ACAATGATTG CTGTCCCGTA GTATTTTGCA	2128		
	AAACCTTCTA GCCCTCAGTT GTTCTGGCTT TTTTGTGCAT TGCATTATAA TGA CTGGATG	2188		
55	TATGATTTGC AAGAATTGCA GAAGTCCCCA TTTGCTTGTT GTGGAANCCC CAGATCAAAA	2248		

-43-

AGCCCTGTTA TGGCACTCAC ACCCTATCCA CTTACCAGG AAAAAAAAAA AATCAAAAAA 2308

AAAAAAAAAA AAAAAAGAA AAAAAAAAAA AAAAAGGAAT TCC 2351

5

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 602 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Trp Ala Thr Ser Glu Gly Pro Leu Gln Tyr Ser Leu Ala Pro Thr  
1 5 10 15

Gln Thr Asp Val Asn Ser Ser Tyr Ser Thr Val Pro Pro Lys Leu Lys  
20 25 30

Glu Met Glu Asn Gln Glu Val Ala Val Gly Gln Lys Leu Val Leu Arg  
25 35 40 45

Cys Glu Thr Thr Ser Glu Tyr Pro Ala Leu Arg Phe Lys Trp Leu Lys  
50 55 60

Asn Gly Lys Glu Ile Thr Lys Lys Asn Arg Pro Glu Asn Val Lys Ile  
30 65 70 75 80

Pro Lys Lys Gln Lys Lys Tyr Ser Glu Leu His Ile Tyr Arg Ala Thr  
85 90 95

Leu Ala Asp Ala Gly Glu Tyr Ala Cys Arg Val Ser Ser Lys Leu Gly  
35 100 105 110

Asn Asp Ser Thr Lys Ala Ser Val Ile Ile Thr Asp Thr Asn Ala Thr  
40 115 120 125

Ser Thr Ser Thr Thr Gly Thr Ser His Leu Thr Lys Cys Asp Ile Lys  
130 135 140

Gln Lys Ala Phe Cys Val Asn Gly Gly Glu Cys Tyr Met Val Lys Asp  
45 145 150 155 160

Leu Pro Asn Pro Pro Arg Tyr Leu Cys Arg Cys Pro Asn Glu Phe Thr  
165 170 175

Gly Asp Arg Cys Gln Asn Tyr Val Met Ala Ser Phe Tyr Lys His Leu  
50 180 185 190

Gly Ile Glu Phe Met Glu Ala Glu Glu Leu Tyr Gln Lys Arg Val Leu  
55

	195	200	205
	Thr Ile Thr Gly Ile Cys	Ile Ala Leu Leu Val	Val Gly Ile Met Cys
	210	215	220
5	Val Val Ala Tyr Cys Lys Thr Lys Lys Gln Arg Lys Lys Leu His Asp		
	225	230	235 240
10	Arg Leu Arg Gln Ser Leu Arg Ser Glu Arg Asn Asn Val Met Asn Met		
		245	250 255
	Ala Asn Gly Pro His His Pro Asn Pro Pro Pro Asp Asn Val Gln Leu		
		260	265 270
15	Val Asn Gln Tyr Val Ser Lys Asn Ile Ile Ser Ser Glu Arg Val Val		
		275	280 285
	Glu Arg Glu Thr Glu Thr Ser Phe Ser Thr Ser His Tyr Thr Ser Thr		
		290	295 300
20	Thr His His Ser Met Thr Val Thr Gln Thr Pro Ser His Ser Trp Ser		
		305	310 315 320
	Asn Gly His Thr Glu Ser Ile Leu Ser Glu Ser His Ser Val Leu Val		
25		325	330 335
	Ser Ser Ser Val Glu Asn Ser Arg His Thr Ser Pro Thr Gly Pro Arg		
		340	345 350
30	Gly Arg Leu Asn Gly Ile Gly Gly Pro Arg Glu Gly Asn Ser Phe Leu		
		355	360 365
	Arg His Ala Arg Glu Thr Pro Asp Ser Tyr Arg Asp Ser Pro His Ser		
		370	375 380
35	Glu Arg Tyr Val Ser Ala Met Thr Thr Pro Ala Arg Met Ser Pro Val		
		385	390 395 400
	Asp Phe His Thr Pro Thr Ser Pro Lys Ser Pro Pro Ser Glu Met Ser		
40		405	410 415
	Pro Pro Val Ser Ser Leu Thr Ile Ser Ile Pro Ser Val Ala Val Ser		
		420	425 430
45	Pro Phe Met Asp Glu Glu Arg Pro Leu Leu Leu Val Thr Pro Pro Arg		
		435	440 445
	Leu Arg Glu Lys Tyr Asp Asn His Leu Gln Gln Phe Asn Ser Phe His		
		450	455 460
50	Asn Asn Pro Thr His Glu Ser Asn Ser Leu Pro Pro Ser Pro Leu Arg		
		465	470 475 480
	Ile Val Glu Asp Glu Glu Tyr Glu Thr Thr Gln Glu Tyr Glu Pro Ala		
55		485	490 495

-45-

5           Gln Glu Pro Pro Lys Lys Leu Thr Asn Ser Arg Arg Val Lys Arg Thr  
                   500                               505                               510  
 10       Lys Pro Asn Gly His Ile Ser Ser Arg Val Glu Val Asp Ser Asp Thr  
                   515                               520                               525  
 15       Ser Ser Gln Ser Thr Ser Ser Glu Ser Glu Thr Glu Asp Glu Arg Ile  
                   530                               535                               540  
           Gly Glu Asp Thr Pro Phe Leu Ser Ile Gln Asn Pro Met Thr Thr Ser  
           545                               550                               555                               560  
 20       Leu Glu Pro Ala Ser Ala Tyr Arg Leu Ala Glu Asn Arg Thr Asn Pro  
                   565                               570                               575  
           Thr Asn Arg Phe Ser Thr Pro Glu Glu Leu Gln Ala Arg Leu Ser Ser  
                   580                               585                               590  
           Val Ile Ala Asn Gln Asp Pro Ile Ala Val  
                   595                               600

25

(2) INFORMATION FOR SEQ ID NO:3:

30       (i) SEQUENCE CHARACTERISTICS:  
           (A) LENGTH: 693 base pairs  
           (B) TYPE: nucleic acid  
           (C) STRANDEDNESS: both  
           (D) TOPOLOGY: linear

35       (ii) MOLECULE TYPE: cDNA

40       (ix) FEATURE:  
           (A) NAME/KEY: CDS  
           (B) LOCATION: 1..693

45       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

48       CCC AGA TTG AAA GAA ATG AAG AGC CAG GAG TCA GCT GCA GGC TCC AAG  
 45       Pro Arg Leu Lys Glu Met Lys Ser Gln Glu Ser Ala Ala Gly Ser Lys  
           1                               5                               10                               15  
           CTA GTG CTC CGG TGC GAA ACC AGC TCC GAG TAC TCC TCA CTC AGA TTC       96  
           Leu Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser Ser Leu Arg Phe  
 50                               20                               25                               30  
           AAA TGG TTC AAG AAT GGG AAC GAG CTG AAC CGC AAA AAT AAA CCA GAA       144  
           Lys Trp Phe Lys Asn Gly Asn Glu Leu Asn Arg Lys Asn Lys Pro Glu  
                   35                               40                               45  
 55

-46-

	AAC ATC AAG ATA CAG AAC AAG CCA GGG AAG TCA GAG CTT CGA ATT AAC	192
	Asn Ile Lys Ile Gln Asn Lys Pro Gly Lys Ser Glu Leu Arg Ile Asn	
	50 55 60	
5	AAA GCA TCC CTG GCT GAC TCT GGA GAG TAT ATG TGC AAA GTG ATC AGC	240
	Lys Ala Ser Leu Ala Asp Ser Gly Glu Tyr Met Cys Lys Val Ile Ser	
	65 70 75 80	
10	AAG TTA GGA AAT GAC AGT GCC TCT GCC AAC ATC ACC ATT GTT GAG TCA	288
	Lys Leu Gly Asn Asp Ser Ala Ser Ala Asn Ile Thr Ile Val Glu Ser	
	85 90 95	
15	AAC GAG TTC ATC ACT GGC ATG CCA GCC TCG ACT GAG ACA GCC TAT GTG	336
	Asn Glu Phe Ile Thr Gly Met Pro Ala Ser Thr Glu Thr Ala Tyr Val	
	100 105 110	
20	TCC TCA GAG TCT CCC ATT AGA ATC TCA GTT TCA ACA GAA GGC GCA AAC	384
	Ser Ser Glu Ser Pro Ile Arg Ile Ser Val Ser Thr Glu Gly Ala Asn	
	115 120 125	
25	ACT TCT TCA TCC ACA TCA ACA TCC ACG ACT GGG ACC AGC CAT CTC ATA	432
	Thr Ser Ser Ser Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu Ile	
	130 135 140	
30	AAG TGT GCG GAG AAG GAG AAA ACT TTC TGT GTG AAT GGG GGC GAG TGC	480
	Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys	
	145 150 155 160	
35	TTC ACG GTG AAG GAC CTG TCA AAC CCG TCA AGA TCC TTG TGC AAG TGC	528
	Phe Thr Val Lys Asp Leu Ser Asn Pro Ser Arg Ser Leu Cys Lys Cys	
	165 170 175	
40	CCA AAT GAG TTT ACT GGT GAT CGT TGC CAA AAC TAC GTA ATG GCC AGC	576
	Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val Met Ala Ser	
	180 185 190	
45	TTC TAC AAG CAT CTT GGG ATT GAA TTT ATG GAA GCG GAG GAA CTC TAC	624
	Phe Tyr Lys His Leu Gly Ile Glu Phe Met Glu Ala Glu Glu Leu Tyr	
	195 200 205	
50	CAG AAG AGG GTG CTG ACA ATT ACT GGC ATC TGT ATC GCC CTG CTG GTG	672
	Gln Lys Arg Val Leu Thr Ile Thr Gly Ile Cys Ile Ala Leu Leu Val	
	210 215 220	
55	GTC GGC ATC ATG TGT GTG GTG	693
	Val Gly Ile Met Cys Val Val	
	225 230	

50 (2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 231 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

55



-47-

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

5 Pro Arg Leu Lys Glu Met Lys Ser Gln Glu Ser Ala Ala Gly Ser Lys  
    1                  5                  10                  15  
 10 Leu Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser Ser Leu Arg Phe  
                   20                  25                  30  
 Lys Trp Phe Lys Asn Gly Asn Glu Leu Asn Arg Lys Asn Lys Pro Glu  
           35                  40                  45  
 15 Asn Ile Lys Ile Gln Asn Lys Pro Gly Lys Ser Glu Leu Arg Ile Asn  
       50                  55                  60  
 Lys Ala Ser Leu Ala Asp Ser Gly Glu Tyr Met Cys Lys Val Ile Ser  
       65                  70                  75                  80  
 20 Lys Leu Gly Asn Asp Ser Ala Ser Ala Asn Ile Thr Ile Val Glu Ser  
                   85                  90                  95  
 Asn Glu Phe Ile Thr Gly Met Pro Ala Ser Thr Glu Thr Ala Tyr Val  
 25                  100                  105                  110  
 Ser Ser Glu Ser Pro Ile Arg Ile Ser Val Ser Thr Glu Gly Ala Asn  
           115                  120                  125  
 30 Thr Ser Ser Ser Thr Ser Thr Ser Thr Thr Gly Thr Ser His Leu Ile  
       130                  135                  140  
 Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys  
   145                  150                  155                  160  
 35 Phe Thr Val Lys Asp Leu Ser Asn Pro Ser Arg Ser Leu Cys Lys Cys  
           165                  170                  175  
 Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val Met Ala Ser  
 40                  180                  185                  190  
 Phe Tyr Lys His Leu Gly Ile Glu Phe Met Glu Ala Glu Glu Leu Tyr  
       195                  200                  205  
 45 Gln Lys Arg Val Leu Thr Ile Thr Gly Ile Cys Ile Ala Leu Leu Val  
       210                  215                  220  
 Val Gly Ile Met Cys Val Val  
   225                  230  
 50

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

55 (A) LENGTH: 7 amino acids

-48-

(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Asn Arg Pro Glu Asn Val Lys  
1 5

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Ala Thr Leu Ala Asp Ala Gly Glu Tyr Ala Cys Arg  
1 5 10

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 15 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GCCGARAAYG TNAAG

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

15

(A) LENGTH: 16 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: cDNA

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

CKRCAGCRTA YTCNCC 16

(2) INFORMATION FOR SEQ ID NO:9:

15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 97 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
20 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GGCCCCGGAAA TGTCAAGATC CCCAAAAAGC AAAAGAAATA CTCTGAGCTT CATATTTATA 60

30 GAGCCACGTT GGCTGACGCT GGGGAATACG CCTGCCG 97

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22 base pairs  
(B) TYPE: nucleic acid  
40 (C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

GCGCAAACAC TTCTTCATCC AC 22

50 (2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 8 amino acids  
55 (B) TYPE: amino acid

-50-

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

5 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

10 Gly Ala Asn Thr Ser Ser Ser Thr  
1 5

(2) INFORMATION FOR SEQ ID NO:12:

15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 21 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
20 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CACCACACAC ATGATGCCGA C 21

30 (2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 7 amino acids  
(B) TYPE: amino acid  
35 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

45 Val Gly Ile Met Cys Val Val  
1 5

(2) INFORMATION FOR SEQ ID NO:14:

50 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 22 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
55 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

CACGACTAGT ACTAGCCATC TC

22

(2) INFORMATION FOR SEQ ID NO:15:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

15

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CGACAAGCTT CTAGTAGAGT TCC

23

25 (2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 24 base pairs

(B) TYPE: nucleic acid

30

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CATTTTACCT TTCGCTATGA GGAG

24

40

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs

45

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

55 GCGCAAACAC TTCTTCATCC AC

22

## (2) INFORMATION FOR SEQ ID NO:18:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 22 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## 10 (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

15 CTCATCTTCG GCGAGATGTC TG 22

## (2) INFORMATION FOR SEQ ID NO:19:

## (i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 23 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## 25 (ii) MOLECULE TYPE: cDNA

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

30 TGCAAAGTGA TCAGCAAGTT AGG 23

## (2) INFORMATION FOR SEQ ID NO:20:

## (i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## 40 (ii) MOLECULE TYPE: peptide

## (v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

50 Thr Lys Ala Ser Val Ile Ile Thr Asp Thr Asn Ala  
1 5 10

## (2) INFORMATION FOR SEQ ID NO:21:

## (i) SEQUENCE CHARACTERISTICS:

- 55 (A) LENGTH: 23 base pairs

-53-

(B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

5 (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

10

CAGATTGAAA GAAATGAAGA GCC

23

(2) INFORMATION FOR SEQ ID NO:22:

15

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 40 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

20

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

25 Cys Asp Ile Lys Gln Lys Ala Phe Cys Val Asn Gly Gly Glu Cys Tyr  
     1                    5                    10                    15

Met Val Lys Asp Leu Pro Asn Pro Pro Arg Tyr Leu Cys Arg Cys Pro  
                     20                    25                    30

30

Asn Glu Phe Thr Gly Asp Arg Cys  
                     35                    40

35 (2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 40 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

40

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

45

Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu Cys Phe  
     1                    5                    10                    15

50 Thr Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu Cys Lys Cys Pro  
                     20                    25                    30

Asn Glu Phe Thr Gly Asp Arg Cys  
                     35                    40

55

## (2) INFORMATION FOR SEQ ID NO:24:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 26 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

10

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Met Trp Ala Thr Ser Glu Gly Pro Leu Gln Tyr Ser Leu Ala Pro Thr  
 1 5 10 15  
 Glu Thr Asp Val Ser Ser Tyr Asn Thr Val  
 20 25

## (2) INFORMATION FOR SEQ ID NO:25:

20

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 12 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

25

## (ii) MOLECULE TYPE: peptide

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

30 Thr Lys Ala Ser Val Ile Ile Thr Asp Thr Asn Ala  
 1 5 10

## 35 (2) INFORMATION FOR SEQ ID NO:26:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 113 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

40

## (ii) MOLECULE TYPE: peptide

## 45 (v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

50

Cys Asp Ile Lys Gln Lys Ala Phe Cys Val Asn Gly Gly Glu Cys Tyr  
 1 5 10 15

55 Met Val Lys Asp Leu Pro Asn Pro Pro Arg Tyr Leu Cys Arg Cys Pro  
 20 25 30



-55-

Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val Met Gly Ser Phe  
                   35                  40                  45  
 5 Tyr Lys His Leu Gly Ile Glu Phe Met Glu Ala Glu Glu Leu Tyr Gln  
                   50                  55                  60  
 Lys Arg Val Leu Thr Ile Thr Gly Ile Cys Ile Ala Leu Leu Val Val  
                   65                  70                  75                  80  
 10 Gly Ile Met Cys Val Val Ala Tyr Cys Lys Thr Lys Lys Glu Arg Lys  
                   85                  90                  95  
 Lys Leu His Asp Arg Leu Arg Gln Ser Leu Arg Ser Glu Arg Asn Asn  
 15                  100                  105                  110  
 Val

20 (2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:  
       (A) LENGTH: 30 amino acids  
       (B) TYPE: amino acid  
 25 (C) STRANDEDNESS: single  
       (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

30 (v) FRAGMENT TYPE: internal

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

Cys Asp Ile Lys Gln Lys Ala Phe Cys Val Asn Gly Gly Glu Cys Tyr  
   1                  5                  10                  15  
 Met Val Lys Asp Leu Pro Asn Pro Pro Arg Tyr Leu Cys Arg  
 40                  20                  25                  30

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:  
 45 (A) LENGTH: 91 amino acids  
       (B) TYPE: amino acid  
       (C) STRANDEDNESS: single  
       (D) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

55

-56-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Cys Asp Ile Lys Gln Lys Ala Phe Cys Val Asn Gly Gly Glu Cys Tyr  
 1 5 10 15  
 Met Val Lys Asp Leu Pro Ser Pro Pro Arg Tyr Leu Cys Arg Cys Ser  
 20 25 30  
 Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val Met Ala Ser Phe  
 35 40 45  
 Tyr Lys His Leu Gly Ile Glu Phe Met Ala Glu Glu Leu Tyr Gln Lys  
 50 55 60  
 Arg Val Leu Thr Ile Thr Gly Ile Cys Ile Ala Leu Leu Val Val Gly  
 65 70 75 80  
 Ile Met Cys Val Val Ala Tyr Cys Lys Thr Lys  
 85 90

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 30 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Cys Asp Ile Lys Gln Lys Ala Phe Cys Val Asn Gly Gly Glu Cys Tyr  
 1 5 10 15  
 Met Val Lys Asp Leu Pro Asn Pro Pro Arg Tyr Leu Cys Arg  
 20 25 30

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 81 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

-57-

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

5 Cys Asp Ile Lys Gln Lys Ala Phe Cys Val Asn Gly Gly Glu Cys Tyr  
 1 5 10 15  
 Met Val Lys Asp Leu Pro Asn Pro Pro Arg Tyr Leu Cys Arg Cys Pro  
 20 25 30  
 10 Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val Met Ala Ser Phe  
 35 40 45  
 Tyr Lys His Leu Gly Ile Glu Phe Met Glu Ala Glu Glu Leu Tyr Gln  
 50 55 60  
 15 Lys Arg Val Leu Thr Ile Thr Gly Ile Cys Ile Ala Gln Gln Gln Ser  
 65 70 75 80  
 20 Lys

## (2) INFORMATION FOR SEQ ID NO:31:

25 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 83 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

40 Cys Asp Ile Lys Gln Lys Ala Phe Cys Val Asn Gly Gly Glu Cys Tyr  
 1 5 10 15  
 Met Val Lys Asp Leu Pro Asn Pro Pro Arg Tyr Leu Cys Arg Cys Pro  
 20 25 30  
 45 Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val Met Ala Ser Phe  
 35 40 45  
 Tyr Lys His Leu Gly Ile Glu Phe Met Ala Glu Glu Leu Tyr Gln Lys  
 50 55 60  
 50 Arg Val Leu Thr Ile Thr Gly Ile Cys Ile Ala Leu Leu Val Val Gly  
 65 70 75 80  
 Ile Met Cys

55

## (2) INFORMATION FOR SEQ ID NO:32:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 90 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

10

## (v) FRAGMENT TYPE: internal

## 15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Ser Ala Asn Ile Thr Ile Val Glu Ser Asn Ala Thr Ser Thr Ser Thr  
 1 5 10 15

20 Thr Gly Thr Ser His Leu Ile Lys Cys Ala Glu Lys Glu Lys Thr Phe  
 20 25 30

Cys Val Asn Gly Gly Glu Cys Phe Thr Val Lys Asp Leu Ser Asn Pro  
 35 40 45

25

Ser Arg Tyr Leu Cys Lys Cys Pro Asn Glu Phe Thr Gly Asp Arg Cys  
 50 55 60

30 Gln Asn Tyr Val Met Ala Ser Phe Tyr Lys His Leu Gly Ile Glu Phe  
 65 70 75 80

Met Glu Ala Glu Glu Leu Tyr Gln Lys Arg  
 85 90

## 35 (2) INFORMATION FOR SEQ ID NO:33:

## (i) SEQUENCE CHARACTERISTICS:

- 40 (A) LENGTH: 165 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

45

## (v) FRAGMENT TYPE: internal

## 50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

Ala Gly Ser Lys Leu Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser  
 1 5 10 15

55 Ser Leu Arg Phe Lys Trp Phe Lys Asn Gly Asn Glu Leu Asn Arg Arg  
 20 25 30

-59-

Asn Lys Pro Glu Asn Ile Lys Ile Gln Lys Lys Pro Gly Lys Ser Glu  
                   35                                  40                                  45  
 5    Leu Arg Ile Asn Lys Ala Ser Leu Ala Asp Ser Gly Glu Tyr Met Cys  
           50                                  55                                  60  
       Lys Val Ile Ser Lys Leu Gly Asn Asp Ser Ala Ser Ala Asn Ile Thr  
       65                                  70                                  75                                  80  
 10    Ile Val Glu Ser Asn Ala Thr Ser Thr Ser Thr Thr Gly Thr Ser His  
                                   85                                  90                                  95  
       Leu Ile Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly  
                                   100                                  105                                  110  
       Glu Cys Phe Thr Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu Cys  
                                   115                                  120                                  125  
 20    Lys Cys Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn Tyr Val Met  
                                   130                                  135                                  140  
       Ala Ser Phe Tyr Lys His Leu Gly Ile Glu Phe Met Glu Ala Glu Glu  
       145                                  150                                  155                                  160  
 25    Leu Tyr Gln Lys Arg  
                                   165

## (2) INFORMATION FOR SEQ ID NO:34:

30

- (i) SEQUENCE CHARACTERISTICS:  
       (A) LENGTH: 106 amino acids  
       (B) TYPE: amino acid  
       (C) STRANDEDNESS: single  
       (D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

40

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

45

Ser Ala Asn Ile Thr Ile Val Glu Ser Asn Glu Phe Ile Thr Gly Met  
 1                                  5                                  10                                  15

Pro Ala Ser Thr Glu Thr Ala Tyr Val Ser Ser Glu Ser Pro Ile Arg  
                                   20                                  25                                  30

50

Ile Ser Val Ser Thr Glu Gly Ala Asn Thr Ser Ser Ser Thr Ser Thr  
                                   35                                  40                                  45

55

Ser Thr Thr Gly Thr Ser His Leu Ile Lys Cys Ala Glu Lys Glu Lys  
 50                                  55                                  60

-60-

Thr Phe Cys Val Asn Gly Gly Glu Cys Phe Thr Val Lys Asp Leu Ser  
 65 70 75 80

5 Asn Pro Ser Arg Tyr Leu Cys Lys Cys Pro Asn Glu Phe Thr Gly Asp  
 85 90 95

Arg Cys Gln Asn Tyr Val Met Ala Ser Phe  
 100 105

10

## (2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 109 amino acids  
 15 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide  
 20

(v) FRAGMENT TYPE: internal

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

Ala Gly Ser Lys Leu Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser  
 1 5 10 15

30 Ser Leu Arg Phe Lys Trp Phe Lys Asn Gly Asn Glu Leu Asn Arg Arg  
 20 25 30

Asn Lys Pro Glu Asn Ile Lys Ile Gln Lys Lys Pro Gly Lys Ser Glu  
 35 35 40 45

Leu Arg Ile Asn Lys Ala Ser Leu Ala Asp Ser Gly Glu Tyr Met Cys  
 50 55 60

40 Lys Val Ile Ser His Leu Gly Asn Asp Ser Ala Ser Ala Asn Ile Thr  
 65 70 75 80

Ile Val Glu Ser Asn Ala Thr Ser Thr Ser Thr Thr Gly Thr Ser His  
 85 90 95

45 Leu Ile Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val  
 100 105

## (2) INFORMATION FOR SEQ ID NO:36:

50 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 100 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 55 (D) TOPOLOGY: linear

-61-

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Ala Gly Ser Lys Leu Val Leu Arg Cys Glu Thr Ser Ser Glu Tyr Ser  
 1 5 10 15  
 Ser Leu Arg Phe Lys Trp Phe Lys Asn Gly Asn Glu Leu Asn Arg Lys  
 20 25 30  
 Asn Lys Pro Glu Asn Ile Lys Ile Gln Lys Lys Pro Gly Lys Ser Glu  
 35 40 45  
 Leu Arg Ile Thr Lys His Pro Trp Leu Thr Leu Glu Ser Ile Cys Ala  
 50 55 60  
 Asn Thr Ser Ser Ser Thr Ser Thr Ser Thr Gly Thr Ser His Leu  
 65 70 75 80  
 Ile Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly Glu  
 85 90 95  
 Cys Phe Thr Val  
 100

30

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 45 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: peptide

40

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

45

Leu Val Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly  
 1 5 10 15  
 Glu Cys Phe Met Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu Cys  
 20 25 30  
 Lys Cys Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn  
 35 40 45

55

-62-

## (2) INFORMATION FOR SEQ ID NO:38:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 45 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

Leu Ile Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly  
 1 5 10 15  
 Glu Cys Phe Thr Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu Cys  
 20 25 30  
 Lys Cys Pro Asn Glu Phe Thr Gly Asp Arg Cys Gln Asn  
 35 40 45

## (2) INFORMATION FOR SEQ ID NO:39:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 45 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: peptide

## (v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Leu Val Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly  
 1 5 10 15  
 Glu Cys Phe Met Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu Cys  
 20 25 30  
 Lys Cys Gln Pro Gly Phe Thr Gly Ala Arg Cys Thr Glu  
 35 40 45

## (2) INFORMATION FOR SEQ ID NO:40:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 45 amino acids  
 (B) TYPE: amino acid



-63-

(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

5

(v) FRAGMENT TYPE: internal

10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Leu Val Lys Cys Ala Glu Lys Glu Lys Thr Phe Cys Val Asn Gly Gly  
1 5 10 15

15 Glu Cys Phe Thr Val Lys Asp Leu Ser Asn Pro Ser Arg Tyr Leu Cys  
20 25 30

20 Lys Cys Gln Pro Gly Phe Thr Gly Ala Arg Cys Thr Glu  
35 40 45

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:  
25 (A) LENGTH: 41 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

35

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Arg Asp Pro Cys Leu Arg Lys Tyr Lys Asp Phe Cys Ile His Gly Glu  
1 5 10 15

40

Cys Lys Tyr Val Lys Glu Leu Arg Ala Pro Ser Cys Ile Cys His Pro  
20 25 30

45 Gly Tyr His Gly Glu Arg Cys His Gly  
35 40

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:  
50 (A) LENGTH: 41 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

55 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Lys Asn Pro Cys Asn Ala Glu Phe Gln Asn Phe Cys Ile His Gly Glu  
1 5 10 15  
Cys Lys Tyr Ile Glu His Leu Glu Ala Val Thr Cys Lys Cys Gln Gln  
20 25 30  
Glu Tyr Phe Gly Glu Arg Cys Gly Glu  
15 35 40

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:  
20 (A) LENGTH: 40 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

Lys Asn Pro Cys Ala Ala Lys Gln Asn Phe Cys Ile His Gly Glu Cys  
1 5 10 15  
35 Arg Tyr Ile Glu Asn Leu Glu Val Val Thr Cys His Cys His Gln Asp  
20 25 30  
Tyr Phe Gly Glu Arg Cys Gly Glu  
40 35 40

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:  
45 (A) LENGTH: 42 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

50 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

55

-65-

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

Asp Ser Glu Cys Pro Leu Ser His Asp Gly Tyr Cys Leu His Asp Gly  
 1                      5                      10                      15  
 Val Cys Met Tyr Ile Glu Ala Leu Asp Lys Tyr Ala Cys Asn Cys Val  
                     20                      25                      30  
 Val Gly Tyr Ile Gly Glu Arg Cys Gln Tyr  
 10                      35                      40

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:  
 15        (A) LENGTH: 41 amino acids  
           (B) TYPE: amino acid  
           (C) STRANDEDNESS: single  
           (D) TOPOLOGY: linear

20        (ii) MOLECULE TYPE: peptide

          (v) FRAGMENT TYPE: internal

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

Phe Asn Asp Cys Pro Asp Ser His Thr Gln Phe Cys Phe His Gly Thr  
 1                      5                      10                      15  
 Cys Arg Phe Leu Val Gln Glu Asp Lys Pro Ala Cys Val Cys His Ser  
 30                      20                      25                      30  
 Gly Tyr Val Gly Ala Arg Cys Glu His  
 35                      35                      40

Claims

1. An isolated neurotrophic factor, which induces the formation of ion channels in a surface membrane of a cell, comprising an EGF-like amino acid sequence, and a second amino acid sequence encoded by at least a portion of an exon of the neurotrophic factor gene expressible in a neuronal cell.
2. The neurotrophic factor of claim 1, wherein the EGF-like amino acid sequence is represented by the formula  $CX_1CX_2CX_3CX_4CX_5C$ , where C is a cysteine,  $X_1$  represents 4 to 14 amino acids which can be the same or different,  $X_2$  represents 3 to 8 amino acids which can be the same or different,  $X_3$  represents 4 to 14 amino acids which can be the same or different,  $X_4$  is any amino acid, and  $X_5$  represents 8 to 14 amino acids which can be the same or different.
3. The neurotrophic factor of claim 1, wherein the EGF-like amino acid sequence is identical or substantially similar to  
Cys-Asp-Ile-Lys-Gln-Lys-Ala-Phe-Cys-Val- Asn-Gly-Gly-Glu-Cys-Tyr-Met-  
Val-Lys-Asp- Leu-Pro-Asn-Pro-Pro-Arg-Tyr-Leu-Cys-Arg- Cys-Pro-Asn-Glu-  
Phe-Thr-Gly-Asp-Arg-Cys
4. The neurotrophic factor of claim 1, wherein the EGF-like amino acid sequence is identical or substantially similar to  
Cys-Ala-Glu-Lys-Glu-Lys-Thr-Phe-Cys-Val- Asn-Gly-Gly-Glu-Cys-Phe-Thr-  
Val-Lys-Asp- Leu-Ser-Asn-Pro-Ser-Arg-Tyr-Leu-Cys-Lys-Cys-Pro-Asn-Glu-  
Phe-Thr-Gly-Asp-Arg-Cys
5. The neurotrophic factor of claim 1, wherein the second amino acid sequence is identical or substantially similar to an amino acid sequence selected from the group consisting of  
Met-Trp-Ala-Thr-Ser-Glu-Gly-Pro-Leu-Gln-Tyr- Ser-Leu-Ala-Pro-Thr-Glu-Thr-  
Asp-Val-Asn-Ser- Ser-Tyr-Asn-Thr-Val ,  
Thr-Lys-Ala-Ser-Val-Ile-Ile-Thr-Asp-Thr-Asn- Ala ,  
and a combination thereof.
6. The neurotrophic factor of claim 1, wherein the ion channel is a directly ligand-gated ion channel.

7. The neurotrophic factor of claim 6, wherein the directly ligand-gated ion channel is a cholinergic receptor.
8. The neurotrophic factor of claim 7, wherein the cholinergic receptor is a nicotinic acetylcholine receptor.
9. The neurotrophic factor of claim 6, wherein the directly ligand-gated ion channel is selected from a group consisting of an acetylcholine receptor, a glutamatergic receptor, a GABA receptor, a glycine receptor, and a combination thereof.
10. The neurotrophic factor of claim 1, wherein the ion channel is a voltage-gated ion channel.
11. The neurotrophic factor of claim 1, wherein the ion channel is an indirectly ligand-gated ion channel.
12. The neurotrophic factor of claim 11, wherein the indirectly ligand-gated ion channelolinergic receptor is a muscarinic acetylcholine receptor.
13. The neurotrophic factor of claim 1, wherein the cell is a muscle cell.
14. The neurotrophic factor of claim 1, wherein the cell is a nerve cell.
15. The neurotrophic factor of claim 1, wherein the neurotrophic factor is a glycoprotein.
16. The neurotrophic factor of claim 1, wherein the factor is a protein derived from an avian gene.
17. The neurotrophic factor of claim 1, wherein the factor is a protein derived from a mammalian gene.
18. Isolated DNA encoding the neurotrophic factor of claim 1.
19. An expression vector comprising the DNA of claim 18.
20. A cell transformed with the expression vector of claim 19.

21. A neurotrophic protein, which induces the formation of ion channels in a surface membrane of a cell, having an amino acid sequence shown in Figure 1, or any functional fragments thereof or amino acid sequence substantially similar thereto.
- 5 22. Isolated DNA encoding the neurotrophic protein of claim 21.
23. An expression vector comprising the DNA of claim 22.
- 10 24. A cell transformed with the expression vector of claim 23.
25. Isolated DNA having the nucleotide sequence shown in Figure 1, or a fragment thereof coding for a polypeptide able to induce formation of ion channels in a surface membrane of a cell.
- 15 26. An expression vector comprising the DNA of claim 25.
27. A cell transformed with the expression vector of claim 26.
- 20 28. A method of inducing the formation of ion channels in a surface membrane of a cell comprising treating the cell with an ion channel-inducing protein or polypeptide having an EGF-like amino acid sequence.
29. The method of claim 28 wherein the ion channel is a directly ligand-gated ion channel.
- 25 30. The method of claim 29 wherein the directly ligand-gated ion channel is a cholinergic receptor.
31. The method of claim 30 wherein the cholinergic receptor is a nicotinic acetylcholine receptor.
- 30 32. The method of claim 29 wherein the directly ligand-gated ion channel is selected from a group consisting of an acetylcholine receptor, a glutamatergic receptor, a GABA receptor, a glycine receptor, and a combination thereof.
- 35

33. The method of claim 28 wherein the ion channel is a voltage-gated ion channel.
34. The method of claim 28, wherein the ion channel is an indirectly ligand-gated ion channel.
- 5 35. The method of claim 34, wherein the indirectly ligand-gated ion channelolinergetic receptor is a muscarinic acetylcholine receptor.
36. The method of claim 28 wherein the cell is a muscle cell.
- 10 37. The method of claim 28 wherein the cell is a nerve cell.
38. The method of claim 28, wherein the EGF-like amino acid sequence is represented by the formula  $CX_1CX_2CX_3CX_4CX_5C$ , where C is a cysteine,  $X_1$  represents 4 to 14 amino acids which can be the same or different,  $X_2$  represents 3 to 8 amino acids which can be the same or different,  $X_3$  represents 4 to 14 amino acids which can be the same or different,  $X_5$  is any amino acid, and  $X_5$  represents 8 to 14 amino acids which can be the same or different.
- 15 39. The method of claim 28, wherein the EGF-like amino acid sequence is identical or substantially similar to  
 Cys-Asp-Ile-Lys-Gln-Lys-Ala-Phe-Cys-Val- Asn-Gly-Gly-Glu-Cys-Tyr-Met-  
 Val-Lys-Asp- Leu-Pro-Asn-Pro-Pro-Arg-Tyr-Leu-Cys-Arg- Cys-Pro-Asn-Glu-  
 Phe-Thr-Gly-Asp-Arg-Cys
- 20 40. The method of claim 28, wherein the ion channel-inducing protein further comprises a second amino acid sequence identical or substantially similar to an amino acid sequence selected from the group consisting of  
 Met-Trp-Ala-Thr-Ser-Glu-Gly-Pro-Leu-Gln-Tyr- Ser-Leu-Ala-Pro-Thr-Glu-Thr-  
 Asp-Val-Asn-Ser- Ser-Tyr-Asn-Thr-Val ,  
 30 Thr-Lys-Ala-Ser-Val-Ile-Ile-Thr-Asp-Thr-Asn- Ala ,  
 and a combination thereof.
41. The method of claim 28, wherein the ion channel-inducing protein is selected from a group consisting of a neurotrophic factor of Figure 1, heregulins, Neu differentiation factors, and functionally active portions thereof.
- 35

42. The method of claim 28, wherein the ion channel-inducing protein induces phosphorylation of an approximately 185kD transmembrane protein in the postsynaptic cell.
- 5
43. A method of enhancing formation of a synaptic junction between a neuron and a target cell, comprising treating the target cell with an ion channel-inducing protein or polypeptide having an EGF-like amino acid sequence, and in an amount sufficient to induce the formation of ion channels in a surface membrane of the cell.
- 10
44. The method of claim 43, wherein the EGF-like amino acid sequence is represented by the formula  $CX_1CX_2CX_3CX_4CX_5C$ , where C is a cysteine,  $X_1$  represents 4 to 14 amino acids which can be the same or different,  $X_2$  represents 3 to 8 amino acids which can be the same or different,  $X_3$  represents 4 to 14 amino acids which can be the same or different,  $X_4$  is any amino acid, and  $X_5$  represents 8 to 14 amino acids which can be the same or different.
- 15
45. The method of claim 43, wherein the EGF-like amino acid sequence is identical or substantially similar to
- 20
- Cys-Asp-Ile-Lys-Gln-Lys-Ala-Phe-Cys-Val- Asn-Gly-Gly-Glu-Cys-Tyr-Met-Val-Lys-Asp- Leu-Pro-Asn-Pro-Pro-Arg-Tyr-Leu-Cys-Arg- Cys-Pro-Asn-Glu-Phe-Thr-Gly-Asp-Arg-Cys
46. The method of claim 43, wherein the ion channel-inducing protein further comprises a second amino acid sequence identical or substantially similar to an amino acid sequence selected from the group consisting of
- 25
- Met-Trp-Ala-Thr-Ser-Glu-Gly-Pro-Leu-Gln-Tyr- Ser-Leu-Ala-Pro-Thr-Glu-Thr-Asp-Val-Asn-Ser- Ser-Tyr-Asn-Thr-Val ,
- 30
- Thr-Lys-Ala-Ser-Val-Ile-Ile-Thr-Asp-Thr-Asn- Ala ,
- and a combination thereof.



47. The method of claim 43, wherein the ion channel-inducing protein is selected from a group consisting of a neurotrophic factor of Figure 1, heregulins, Neu differentiation factors, and functionally active portions thereof.
- 5 48. The method of claim 43, wherein the ion channel-inducing protein induces phosphorylation of an approximately 185kD transmembrane protein in the cell.
49. The method of claim 43 wherein the ion channel is a directly ligand-gated ion channel.
- 10 50. The method of claim 49 wherein the directly ligand-gated ion channel is selected from a group consisting of an acetylcholine receptor, a glutamatergic receptor, a GABA receptor, a glycine receptor, and a combination thereof.
- 15 51. The method of claim 43 wherein the ion channel is a voltage-gated ion channel.
52. The method of claim 43, wherein the ion channel is an indirectly ligand-gated ion channel.
- 20 53. The method of claim 52, wherein the indirectly ligand-gated ion channelolinergic receptor is a muscarinic acetylcholine receptor.
54. The method of claim 43, wherein the target cell is a muscle cell.
- 25 55. The method of claim 43, wherein the target cell is a nerve cell.
56. The method of claim 43, wherein the target cell is a glandular cell.
- 30 57. The method of claim 43 wherein enhancement of the formation of synaptic junctions is accomplished in an individual afflicted with a neurological disorder involving abnormal functional synaptic connections.
58. The method of claim 57 wherein the neurological disorder is a neuromuscular disorder.
- 35 59. The method of claim 57, wherein the neurological disorder is a autonomic disorder.

60. The method of claim 57, wherein the neurological disorder is a central nervous system disorder.
61. A therapeutic composition comprising the neurotrophic factor of claim 1 and a physiologically acceptable carrier.
62. An antibody which specifically binds the neurotrophic factor of claim 1.
63. An antibody which specifically binds the neurotrophic protein of claim 15.
64. A method for generating novel ARIA homologs and genes encoding said novel ARIA homologs, comprising:
- (a) transforming suitable host cells with a library of replicable phage vectors encoding a library of phage particles displaying a fusion coat protein, each of said phage vectors comprising a chimeric coat protein gene encoding said fusion coat protein, said chimeric gene including a first gene encoding a candidate ARIA polypeptide, and a second gene encoding at least a portion of a phage coat protein, said first gene mutated at one or more codon positions such that said library of phage vectors encodes a plurality of mutated ARIA polypeptides;
  - (b) culturing said transformed host cells under conditions suitable for forming said phage particles including said fusion coat protein; and
  - (c) selecting any of said phage vectors corresponding to phage particles which display a candidate ARIA polypeptide which is able to bind an ARIA-binding protein.
65. The method of claim 64, wherein said filamentous bacteriophage is selected from a group consisting of M13, fd, and f1, and said phage coat protein is a gene-III protein.
66. The method of claim 64, wherein said transformed host cells are cultured with a helper phage suitable for inducing formation of said phage particles.

**FIGURE 1A**

1/6

GAATTCGGGC	GTCTGCGGG	GG	①												52	
			ATG	TGG	GCC	ACC	TCT	GAA	GGT	CCA	CTT	CAG				
			Met	Trp	Ala	Thr	Ser	Glu	Gly	Pro	Leu	Gln				
			1					5				10				
TAC	AGC	CTG	GCA	CCA	ACA	CAG	ACG	GAC	GTC	AAC	AGC	AGT	TAC	AGC	ACA	100
Tyr	Ser	Leu	Ala	Pro	Thr	Gln	Thr	Asp	Val	Asn	Ser	Ser	Tyr	Ser	Thr	
				15					20					25		
①	GTG	CCT	CCC	AAA	TTG	AAG	GAA	ATG	GAA	AAC	CAA	GAG	GTT	GCT	GTG	GGT
	Val	Pro	Pro	Lys	Leu	Lys	Glu	Met	Glu	Asn	Gln	Glu	Val	Ala	Val	Gly
				30					35					40		148
CAG	AAG	CTA	GTG	CTA	AGG	TGT	GAA	ACC	ACT	TCA	GAG	TAC	CCT	GCG	CTC	196
Gln	Lys	Leu	Val	Leu	Arg	Cys	Glu	Thr	Thr	Ser	Glu	Tyr	Pro	Ala	Leu	
				45				50					55			
AGA	TTC	AAA	TGG	TTA	AAG	AAC	GGG	AAG	GAA	ATA	ACG	AAA	AAA	AAC	AGA	244
Arg	Phe	Lys	Trp	Leu	Lys	Asn	Gly	Lys	Glu	Ile	Thr	Lys	Lys	Asn	Arg	
				60				65					70			
CCC	GAA	AAT	GTC	AAG	ATC	CCC	AAA	AAG	CAA	AAG	AAA	TAC	TCT	GAG	CTT	292
Pro	Glu	Asn	Val	Lys	Ile	Pro	Lys	Lys	Gln	Lys	Lys	Tyr	Ser	Glu	Leu	
				75				80						85		90
CAT	ATT	TAT	AGG	GCC	ACG	TTG	GCT	GAC	GCT	GGG	GAA	TAC	GCA	TGC	AGA	340
His	Ile	Tyr	Arg	Ala	Thr	Leu	Ala	Asp	Ala	Gly	Glu	Tyr	Ala	Cys	Arg	
				95					100					105		
GTG	AGC	AGC	AAA	CTA	GGG	AAC	GAC	AGT	ACT	AAA	GCA	AGT	GTT	ATC	ATC	388
Val	Ser	Ser	Lys	Leu	Gly	Asn	Asp	Ser	Thr	Lys	Ala	Ser	Val	Ile	Ile	
				110					115					120		
ACA	GAC	ACC	AAT	GCC	ACT	TCT	ACA	TCT	ACA	ACT	GGG	ACA	AGT	CAT	CTC	436
Thr	Asp	Thr	Asn	Ala	Thr	Ser	Thr	Ser	Thr	Thr	Gly	Thr	Ser	His	Leu	
				125					130					135		
ACA	AAA	TGT	GAC	ATA	AAG	CAG	AAA	GCC	TTC	TGT	GTA	AAT	GGG	GGA	GAG	484
Thr	Lys	Cys	Asp	Ile	Lys	Gln	Lys	Ala	Phe	Cys	Val	Asn	Gly	Gly	Glu	
				140				145					150			
TGC	TAC	ATG	GTT	AAA	GAC	CTC	CCA	AAC	CCT	CCA	CGA	TAC	CTA	TGC	AGG	532
Cys	Tyr	Met	Val	Lys	Asp	Leu	Pro	Asn	Pro	Pro	Arg	Tyr	Leu	Cys	Arg	
				155					160					165		170
TGC	CCA	AAT	GAA	TTT	ACT	GGT	GAT	CGC	TGC	CAA	AAC	TAC	GTA	ATG	GCC	580
Cys	Pro	Asn	Glu	Phe	Thr	Gly	Asp	Arg	Cys	Gln	Asn	Tyr	Val	Met	Ala	
				175					180					185		
AGC	TTC	TAC	AAG	CAT	CTT	GGG	ATT	GAA	TTT	ATG	GAA	GCT	GAG	GAA	CTG	628
Ser	Phe	Tyr	Lys	His	Leu	Gly	Ile	Glu	Phe	Met	Glu	Ala	Glu	Glu	Leu	
				190					195					200		

## FIGURE 1B

2/6

TAC CAG AAA CGG	⑤	GTG CTG ACC ATA ACT GGC ATT TGC ATT GCT CTT CTA	676
Tyr Gln Lys Arg	205	Val Leu Thr Ile Thr Gly Ile Cys Ile Ala Leu Leu	210 215
GTA GTT GGC ATC ATG TGT GTG GTG GCC TAC TGC	⑤	AAA ACC AAG AAG CAG	724
Val Val Gly Ile Met Cys Val Val Ala Tyr Cys	220 225	Lys Thr Lys Lys Gln	230
AGG AAA AAG TTG CAT GAC CGC CTT CGG CAG AGC CTT CGC TCA GAG AGG			772
Arg Lys Lys Leu His Asp Arg Leu Arg Gln Ser Leu Arg Ser Glu Arg	235 240 245		250
AAC AAC GTT ATG AAC ATG GCA AAT GGG CCA CAC CAC CCC AAC CCA CCA			820
Asn Asn Val Met Asn Met Ala Asn Gly Pro His His Pro Asn Pro Pro	255 260 265		
CCA GAC AAT GTC CAG CTG GTG AAT CAG TAC GTT TCA AAA AAC ATA ATC			868
Pro Asp Asn Val Gln Leu Val Asn Gln Tyr Val Ser Lys Asn Ile Ile	270 275 280		
TCC AGT GAA CGT GTC GTT GAG CGA GAA ACC GAG ACC TCG TTT TCC ACA			916
Ser Ser Glu Arg Val Val Glu Arg Glu Thr Glu Thr Ser Phe Ser Thr	285 290 295		
AGC CAC TAC ACC TCA ACA ACT CAT CAC TCC ATG ACA GTC ACC CAG ACG			964
Ser His Tyr Thr Ser Thr Thr His His Ser Met Thr Val Thr Gln Thr	300 305 310		
CCT AGC CAC AGC TGG AGT AAT GGC CAT ACC GAA AGC ATT CTC TCC GAA			1012
Pro Ser His Ser Trp Ser Asn Gly His Thr Glu Ser Ile Leu Ser Glu	315 320 325 330		
AGC CAC TCC GTG CTC GTC AGC TCC TCA GTG GAG AAT AGC AGG CAC ACC			1060
Ser His Ser Val Leu Val Ser Ser Ser Val Glu Asn Ser Arg His Thr	335 340 345		
AGC CCA ACA GGG CCA CGA GGC CGC CTC AAT GGN ATT GGT GGG CCA AGG			1108
Ser Pro Thr Gly Pro Arg Gly Arg Leu Asn Gly Ile Gly Gly Pro Arg	350 355 360		
GAA GGC AAC AGC TTC CTC CGG CAT GCA AGA GAG ACC CCT GAC TCC TAC			1156
Glu Gly Asn Ser Phe Leu Arg His Ala Arg Glu Thr Pro Asp Ser Tyr	365 370 375		
CGA GAC TCT CCT CAC AGT GAA AGG TAT GTC TCA GCT ATG ACC ACA CCA			1204
Arg Asp Ser Pro His Ser Glu Arg Tyr Val Ser Ala Met Thr Thr Pro	380 385 390		
GCT CGC ATG TCA CCC GTT GAT TTC CAC ACT CCA ACT TCT CCC AAG TCC			1252
Ala Arg Met Ser Pro Val Asp Phe His Thr Pro Thr Ser Pro Lys Ser	395 400 405 410		

**FIGURE 1C**

3/6

CCT CCA TCT GAA ATG TCA CCA CCA GTT TCC AGC TTG ACC ATC TCC ATC	1300
Pro Pro Ser Glu Met Ser Pro Pro Val Ser Ser Leu Thr Ile Ser Ile	
415 420 425	
CCT TCG GTG GCG GTG AGT CCC TTT ATG GAC GAG GAG AGA CCG CTG CTG	1348
Pro Ser Val Ala Val Ser Pro Phe Met Asp Glu Glu Arg Pro Leu Leu	
430 435 440	
TTG GTG ACC CCA CCA CGG CTG CGT GAG AAG TAC GAC AAC CAC CTT CAG	1396
Leu Val Thr Pro Pro Arg Leu Arg Glu Lys Tyr Asp Asn His Leu Gln	
445 450 455	
CAA TTC AAC TCC TTC CAC AAC AAT CCC ACC CAT GAG AGC AAC AGT CTG	1444
Gln Phe Asn Ser Phe His Asn Asn Pro Thr His Glu Ser Asn Ser Leu	
460 465 470	
CCA CCC AGT CCT CTG AGG ATA GTG GAG GAT GAA GAG TAT GAG ACC ACG	1492
Pro Pro Ser Pro Leu Arg Ile Val Glu Asp Glu Glu Tyr Glu Thr Thr	
475 480 485 490	
CAG GAG TAC GAA CCA GCA CAG GAG CCT CCA AAG AAA CTC ACC AAC AGC	1540
Gln Glu Tyr Glu Pro Ala Gln Glu Pro Pro Lys Lys Leu Thr Asn Ser	
495 500 505	
CGG AGG GTG AAA AGA ACA AAG CCC AAT GGC CAT ATT TCC AGC AGG GTA	1588
Arg Arg Val Lys Arg Thr Lys Pro Asn Gly His Ile Ser Ser Arg Val	
510 515 520	
GAA GTG GAC TCC GAC ACA AGC TCT CAG AGC ACT AGC TCT GAG AGC GAA	1636
Glu Val Asp Ser Asp Thr Ser Ser Gln Ser Thr Ser Ser Glu Ser Glu	
525 530 535	
ACA GAA GAT GAA AGA ATA GGT GAG GAT ACA CCA TTT CTT AGC ATA CAA	1684
Thr Glu Asp Glu Arg Ile Gly Glu Asp Thr Pro Phe Leu Ser Ile Gln	
540 545 550	
AAT CCC ATG NCA ACC AGT CTG GAG CCA GCC TCT GCA TAT CGG CTG GCT	1732
Asn Pro Met Xaa Thr Ser Leu Glu Pro Ala Ser Ala Tyr Arg Leu Ala	
555 560 565 570	
GAG AAC AGG ACT AAC CCG NCA AAT CGC TTC TCC ACA CCA GAA GAG TTG	1780
Glu Asn Arg Thr Asn Pro Xaa Asn Arg Phe Ser Thr Pro Glu Glu Leu	
575 580 585	
CAA GCA AGG TTG TCC AGT GTA ATA GCT AAC CAA GAC CCT ATT GCT GTA	1828
Gln Ala Arg Leu Ser Ser Val Ile Ala Asn Gln Asp Pro Ile Ala Val	
590 595 600	
TAAGACATAA ACAAACACA TAGATTCACA TGTAACCTT TATTTTATAT AATGAAGTAT	1888
TCCACCTTTA AATTAAACAA TTTATTTTAT TTTAGCAATT CCGCTGATAG AAAACAAGAG	1948
TGGAAAAAGA AACTTTTATA AATTAAGTAT ACGTATGTAC AAATGTGTTA TGTGCCATAT	2008

**FIGURE 1D**


4/6

GTAGCAATTT TTTACAGTAT TTCCAAAATG GGGAAAGATA TCAATGGTGC CTTTATGTTA	2068
TGTTATGTTG AGAGCAAGTT TTGTACAGCT ACAATGATTG CTGTCCCGTA GTATTTTGCA	2128
AAACCTTCTA GCCCTCAGTT GTTCTGGCTT TTTTGTGCAT TGCATTATAA TGACTGGATG	2188
TATGATTTGC AAGAATTGCA GAAGTCCCCA TTTGCTTGTT GTGGAANCCC CAGATCAAAA	2248
AGCCCTGTTA TGGCACTCAC ACCCTATCCA CTTCACCAGG AAAAAAAAAA AATCAAAAAA	2308
AAAAAAAAAA AAAAAAGAA AAAAAAAAAA AAAAAGGAAT TCC	2351

5/6

FIGURE 2

*Chicken ARIA cDNA*



*Human beregulin-β1 cDNA*



FIGURE 3

	C <sub>1</sub>	C <sub>2</sub>	C <sub>3</sub>	C <sub>4</sub>	C <sub>5</sub>	C <sub>6</sub>
ckARIA-1	L-T-K-C-D-I-K-Q-K-A-F-C-V-N-G-G-E-C-Y-M-V-K-D-L-P-N-P-P-R-Y-L-C-R-C-P-N-E-F-T-G-D-R-C-Q-N					
ck/c-119	L-T-K-C-D-I-K-Q-K-A-F-C-V-N-G-G-E-C-Y-M-V-K-D-L-P-N-P-P-R-Y-L-C-R-stop					
ck/c-124	L-T-K-C-D-I-K-Q-K-A-F-C-V-N-G-G-E-C-Y-M-V-K-D-L-P-s-P-P-R-Y-L-C-R-C-s-N-E-F-T-G-D-R-C-Q-N					
ck/s-93	L-T-K-C-D-I-K-Q-K-A-F-C-V-N-G-G-E-C-Y-M-V-K-D-L-P-N-P-P-R-Y-L-C-R-stop					
rtARIA-1	L-I-K-C-A-E-K-E-K-T-F-C-V-N-G-G-E-C-F-T-V-K-D-L-S-N-P-S-R-Y-L-C-K-C-P-N-E-F-T-G-D-R-C-Q-N					
HRG-β	L-V-K-C-A-E-K-E-K-T-F-C-V-N-G-G-E-C-F-M-V-K-D-L-S-N-P-S-R-Y-L-C-K-C-P-N-E-F-T-G-D-R-C-Q-N					
NDF-β	L-I-K-C-A-E-K-E-K-T-F-C-V-N-G-G-E-C-F-T-V-K-D-L-S-N-P-S-R-Y-L-C-K-C-P-N-E-F-T-G-D-R-C-Q-N					
HRG-α	L-V-K-C-A-E-K-E-K-T-F-C-V-N-G-G-E-C-F-M-V-K-D-L-S-N-P-S-R-Y-L-C-K-C-Q-P-G-F-T-G-A-R-C-T-E					
NDF-α	L-V-K-C-A-E-K-E-K-T-F-C-V-N-G-G-E-C-F-T-V-K-D-L-S-N-P-S-R-Y-L-C-K-C-Q-P-G-F-T-G-A-R-C-T-E					
HB-EGF	R-D-P-C-L-R-K-Y-K-D-F-C-I-H-★-G-E-C-K-Y-V-K-E-L-R-A-P-S-★-★-C-I-C-H-P-G-Y-H-G-E-R-C-H-G					
AREG	K-N-P-C-N-A-E-F-Q-N-F-C-I-H-★-G-E-C-K-Y-I-E-H-L-★-★-E-A-V-T-C-K-C-Q-Q-E-Y-F-G-E-R-C-G-E					
SDGF	K-N-P-C-A-A-K-★-Q-N-F-C-I-H-★-G-E-C-R-Y-I-E-N-L-★-★-E-V-V-T-C-H-C-H-Q-D-Y-F-G-E-R-C-G-E					
EGF	D-S-E-C-P-L-S-H-D-G-Y-C-L-H-D-G-V-C-M-Y-I-E-A-L-★-★-D-K-Y-A-C-N-C-V-V-G-Y-I-I-G-E-R-C-Q-Y					
TGF-α	F-N-D-C-P-D-S-H-T-Q-F-C-F-H-★-G-T-C-R-F-L-V-Q-E-★-★-D-K-P-A-C-V-C-H-S-G-Y-V-G-A-R-C-E-H					

6 / 6



## INTERNATIONAL SEARCH REPORT

Intern al Application No  
PCT/US 93/09298A. CLASSIFICATION OF SUBJECT MATTER  
IPC 5 C12N15/12 A61K37/02 C12P21/08 C07K13/00 C07K15/28

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 5 C07K C12N A61K C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY vol. LV, 1990, NEW YORK, US pages 397 - 406 FALLS, D. ET AL. 'Mr 42,000 ARIA: a protein that may regulate the accumulation of acetylcholine receptors at developing chick neuromuscular junctions' cited in the application see the whole document --- -/--</p>	<p>1,6-10, 13-16, 28-33, 36,37, 41,43, 47, 49-51, 54,55, 57-60</p>

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance  
"E" earlier document but published on or after the international filing date  
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  
"O" document referring to an oral disclosure, use, exhibition or other means  
"P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.  
"&" document member of the same patent family

Date of the actual completion of the international search

11 January 1994

Date of mailing of the international search report

14.02.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Andres, S

## INTERNATIONAL SEARCH REPORT

 Intern al Application No  
 PCT/US 93/09298

C.(Continuation) D CUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	THE JOURNAL OF CELL BIOLOGY vol. 103, no. 2 , August 1986 pages 493 - 507 USDIN, T. & FISCHBACH G. 'Purification and characterization of a polypeptide from chick brain that promotes the accumulation of acetylcholine receptors in chick myotubes' cited in the application see the whole document ---	1,6-10, 13-16, 28-33, 36,37, 41,43, 47, 49-51, 54,55, 57-60
X	SCIENCE vol. 256 , 22 May 1992 , LANCASTER, PA US pages 1205 - 1210 HOLMES, W. ET AL. 'Identification of heregulin, a specific activator of p185erbB2' cited in the application see figure 2C ---	1,2, 17-24, 28,38, 41,43, 47,48,62
A		42
A	BIOTECHNOLOGY vol. 9 , December 1991 , NEW YORK US pages 1373 - 1377 GARRARD, L. ET AL. 'Fab assembly and enrichment in a monovalent phage display system' cited in the application see the whole document ---	64-66
X	CELL vol. 69 , 1 May 1992 , CAMBRIDGE, MA US pages 559 - 572 WEN, D. ET AL. 'Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit' cited in the application see figure 3 ---	1,2,15, 17-24, 28,38, 41,43, 47,48,62
A		42
P,X	US,A,5 237 056 (FISCHBACH, G.D.) 17 August 1993 see the whole document ---	1,6-10, 13-16, 28-33, 36,37, 41,43, 47, 49-51, 54,55, 57-60

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 93/09298

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA vol. 90 , February 1993 , WASHINGTON US pages 1624 - 1628 CORFAS, G. ET AL. 'ARIA, a protein that stimulates acetylcholine receptor synthesis, also induces tyrosine phosphorylation of a 185-kDa muscle transmembrane protein' see the whole document ---	1,28,42, 43,48
P,X	CELL vol. 72, no. 5 , 12 March 1993 , CAMBRIDGE, MA US pages 801 - 815 FALLS, D. ET AL. 'ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the Neu ligand family' see the whole document -----	1-10, 13-16, 18-33, 36-51, 54,55, 57-60

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 93/09298

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
**Remark : Although claims 57-60 and 28-56 (as far as in vivo methods are concerned) are directed to a method of treatment of (diagnostic methods practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.**
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 93/09298

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-5237056	17-08-93	NONE	